小児白血病・リンパ腫　Strategy & Practice

出版社： 中山書店
著者：
発行日： 2021-04-30
分野： 臨床医学：内科  >  小児科学一般
ISBN： 9784521749211
電子書籍版： 2021-04-30 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

11,000 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

11,000 円(税込)

購入する

商品紹介

かつて不治の病だった小児白血病は，層別化治療，支持療法の確立により長期生存率を飛躍的に改善させた．
そして現在，次世代シーケンサーなどゲノム解析により遺伝子の全体像が明らかにされ，分子病態に基づく新たな治療戦略が次々に開発されている．生存率の向上に伴い小児がん経験者数は増加し，彼らが成長とともに遭遇する進学，就職，妊孕性などへの対応を専門家から紹介．

目次

  • 1章　小児造血器腫瘍の検査
    　細胞表面マーカー検査
    　染色体・遺伝子検査
    　ゲノム医療の現状と展望

    2章　急性リンパ性白血病（ALL）
    　ALLの分子病態
    　B前駆細胞性ALLの診断・治療
    　T細胞性ALLの診断・治療
    　Ph染色体陽性ALLの診断・治療
    　成熟B細胞性ALLの診断・治療
    　若年成人（AYA）世代ALLの診断・治療
    　再発ALLの診断・治療
    　ALLの新規治療戦略

    3章　急性骨髄性白血病（AML）
    　AMLの分子病態
    　AMLの診断・治療
    　急性前骨髄球性白血病の診断・治療
    　Down症候群に関連したAMLの診断・治療
    　AMLの新規治療戦略

    4章　乳児急性リンパ性白血病（乳児ALL）
    　乳児ALLの分子病態
    　乳児ALLの診断・治療
    　乳児ALLの新規治療戦略

    5章　慢性骨髄性白血病（CML）
    　小児CMLの分子病態
    　CMLの診断・治療
    　CMLの新規治療戦略

    6章　骨髄異形成症候群・骨髄増殖性疾患
    　小児骨髄異形成症候群の分子病態
    　骨髄異形成症候群の診断・治療
    　若年性骨髄単球性白血病の分子病態
    　若年性骨髄単球性白血病の診断・治療

    7章　リンパ腫・リンパ増殖性疾患
    　リンパ腫の分子病態
    　非Hodgkinリンパ腫の診断・治療
    　Hodgkinリンパ腫の診断・治療
    　自己免疫性リンパ増殖症候群の診断・治療
    　X連鎖性リンパ増殖症候群の診断・治療
    　小児全身性EBV陽性リンパ増殖症の診断・治療

    8章　組織球症
    　組織球症の分子病態
    　Langerhans細胞組織球症の診断・治療
    　若年性黄色肉芽腫の診断・治療
    　Erdheim-Chester病の診断・治療

    9章　小児造血器腫瘍の支持療法
    　感染対策
    　輸血療法
    　小児の緩和ケア

    10章　小児造血器腫瘍の晩期合併症
    　二次がん
    　内分泌代謝障害
    　性腺毒性
    　心毒性
    　長期フォローアップ体制の現状と展望－移行期医療

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 小児造血器腫瘍の検査

P.10 掲載の参考文献
1) Swerdlow SH, et al (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed., Revised ed. Lyon : International Agency for Research on Cancer ; 2017.
 
2) Iwamoto S, et al. Flow cytometric analysis of denovo acute lymphoblastic leukemia in childhood : report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Int J Hematol 2011 ; 94 : 185-92.
 
3) Ohta H, et al. Flow cytometric analysis of de novo acute myeloid leukemia in childhood : report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Int J Hematol 2011 ; 93 : 135-7.
 
4) Tsuganezawa K, et al. Flow cytometric diagnosis of the cell lineage and developmental stage of acute lymphoblastic leukemia by novel monoclonal antibodies specific to human pre-B-cell receptor. Blood 1998 ; 92 : 4317-24.
PubMed
5) Koehler M, et al. Transitionial pre-B-cell acute lymphoblastic leukemia or childhood is associated with favorable prognostic clinical features and an excellent outcome : a Pediatric Oncology Group study. Leukemia 1993 ; 7 : 2064-8.
PubMed
6) Chiaretti S, et al. Diagnosis and subclassification of acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis 2014 ; 6 : e2014073.
PubMed
7) Coustan-Smith E, et al. Early T-cell precursor leukaemia : a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009 ; 10 : 147-56.
 
8) Wada H, et al. Adull T-cell progenitors retain myeloid potential. Nature 2008 ; 452 : 768-72.
 
9) Mullighan CG. Genomic profiling of B-progenitor acute lymphoblastic leukemia. Best Pract Res Clin Haematol 2011 ; 24 : 489-503.
PubMed
10) Kiyokawa N, et al. Significance of CD66c expression in childhood acute lymphoblastic leukemia. Leuk Res 2014 ; 38 : 42-8.
PubMed
11) Bugarin C, et al. Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia. Haematologica 2015 ; 100 : e229-32.
PubMed
12) Hirabayashi S, et al. ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype. Haematologica 2017 ; 102 : 118-29.
PubMed
13) Alexander TB, et al. The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature 2018 ; 562 : 373-9.
PubMed
14) Suzuki K, et al. MEF2D-BCL9 Fusion Gune Is Associated With High-Risk Acute B-Cell Precursor Lymphoblastic Leukemia in Adolescents. J Clin Oncol 2016 ; 34 : 3451-9.
 
15) Ohki K, et al. Clinical and molecular characteristics of MEF2D fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including a novel translocation resulting in MEF2D-HNRNPH1 gene fusion. Haematologica 2019 ; 104 : 128-37.
 
16) Schinnerl D, et al. CD371 cell surface expression : a unique feature of DUX4-rearranged acute lymphoblastic leukemia. Haematologica 2019 ; 104 : e352-5.
PubMed
17) Seki M, et al. Recurrent SPI1 (PU. 1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia. Nat Genet 2017 ; 49 : 1274-81.
PubMed
18) Sakamoto K, et al. Negative CD19 expression is associated with inferior relapse-free survival in children with RUNX1-RUNX1T1-positive acute myeloid leukaemia : results from the Japanese Paediatric Letkaemia/Lymphoma Study Group AML-05 study. Br J Haematol 2019 ; 187 : 372-6.
 
P.15 掲載の参考文献
1) Mitelmam Database of Chromosome Aberrations and Gene Fusions in Cancer Searching the Database https://mitelmandatabase.isb-cgc.org
 
1) Shaffer LG, et al (eds). ISCN : An International System or Humam Cytogenetic Nomenclature. Basel : Karger ; 2016.
 
2) Atlas of Genetics and Cytogenetics in Oncology and Haematology http://atlasgeneticsoncology.org/
 
2) 名越久朗. 造血器腫瘍の診療における間期核FISH法. 谷脇雅史, ほか (編著). 造血器腫瘍アトラス 改訂第5版 形態, 免疫, 染色体から分子細胞治療へ. 東京 : 日本医事新報社 ; 2016. p. 111-21.
 
3) Swerdlow SH, et al (eds). WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th ed., Revised ed. Lyon : International Agency for Research on Cancer ; 2017.
 
3) VYSIS FISH : ALL HEMATOLOGICAL CANCER https://www.molecular.abbott/us/en/products/oncology/all-hematological-cancer
 
4) 滝智彦, 林泰秀. 染色体検査結果とキメラ遺伝子検査結果の食い違い症例の検討. 日小児血液会誌 2009 ; 23 : 310-4.
Medical*Online
4) 染色体異常を見つけたら http://cytogen.jp/index/index.html
 
5) Nachman JB, et al. Outcome of treatment in childen with hypodiploid acute lymphoblastic leukemia. Blood 2007 ; 110 : 1112-5.
 
6) Golub TR, et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA 1995 ; 92 : 4917-21.
 
7) Romana SP, et al. The t (12 ; 21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood 1995 ; 85 : 3662-70.
 
8) Hollink IH, et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinet HOX gene expression pattern. Blood 2011 ; 118 : 3645-56.
 
9) Shiba N, et al. NUP98-NSD1 gene fusion and its related gene expression signature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia. Genes Chromosomes Cancer 2013 ; 52 : 683-93.
PubMed
10) Gruber TA, et al. An Inv (16) (p13.3 q24.3) -encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell 2012 ; 22 : 683-97.
 
11) de Rooij JD, et al. NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. Leukemia 2013 ; 27 : 2280-8.
PubMed
12) Meyer C, et al. The MLL recombinome of acute leukemias in 2013. Leukemia 2013 ; 27 : 2165-76.
PubMed
13) Beverloo HB. Breakpoint heterogeneily in t (10 ; 11) translocation in AML-M4/M5 resulting in fusion or AF10 and MLL is resolved by fluorescent in situ hybridization analysis. Cancer Res 1995 ; 55 : 4220-4.
PubMed
14) Ono R, et al. SEPTIN6, a human homolog to mouse Septin6, is fused to MLL in infant acute myeloid leukemia with complex chromosomal abnormalities involving 11q23 and Xq24. Cancer Res 2002 ; 62 : 333-7.
PubMed
15) Kong XT, et al. Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t (16 ; 21) (p11 ; q22) and identification of a novel transcript. Blood 1997 ; 90 : 1192-9.
 
16) Gamou T, et al. The partner gene of AML1 in t (16 ; 21) myeloid malignancies is a novel member of the MTG8 (ETO) family. Blood 1998 ; 91 : 4028-37.
 
17) 滝智彦. 遺伝学的検査の利用と情報管理 検査依頼から結果報告書まで 染色体検査における個人遺伝情報管理. Lab Clin Pract 2014 ; 32 : 5-8.
 
P.20 掲載の参考文献
1) Swerdlow SH, et al (eds). WHO Classification of Tumourrs of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon : International Agency for Reseach on Cancer ; 2017.
 
2) Gu Z, et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet 2019 ; 51 : 296-307.
PubMed
3) Roberts KG, et al. Targetable kinase-aclivating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014 ; 371 : 1005-15.
PubMed
4) Ueno H, et al. Landscape of Driver Mutations and Their Clinical lmpacts in Pediatric B-cell precursor Acute Lymhoblastic Leukemia. Blood Adv 2020 ; 4 : 5165-73.
 
5) Sandahl JD, et al. The applicability of the WHO Classification in paediatric AML. A NOPHO-AML study. Br J Haematol 2015 ; 169 : 859-67.
PubMed
6) Bolouri H, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med 2018 ; 24 : 103-12.
PubMed
7) Shiba N, et al. Transcriptome analysis offers a comprehensive illustration of the genetic back-ground of pediatric acute mycloid leukemia. Blood Adv 2019 ; 3 : 3157-69.
 
8) Schmitz R, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med 2018 ; 378 : 1396-407.
PubMed
9) Chapuy B, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 2018 ; 24 : 679-90.
PubMed
10) Roberts KG, et al. Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol 2014 ; 32 : 3012-20.
PubMed
11) Murakami N, et al. Integrated molecular profiling of juvenile myelomonocytic leukemia. Blood 2018 ; 131 : 1576-86.
PubMed
12) Stanulla M, et al. IKZF1 (plus) Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. J Clin Oncol 2018 ; 36 : 1240-9.
PubMed
13) Yeoh AEJ, et al. Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival : Results of Malaysia-Singapore ALL 2010 Study. J Clin Oncol 2018 ; 36 : 2726-35.
PubMed
14) O'Connor D, et al. Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia. J Clin Oncol 2018 ; 36 : 34-43.
PubMed
15) Dohner H, et al. Diagnosis and management of AML in adults : 2017 ELN recommendations from an international expert panel. Blood 2017 ; 129 : 424-47.
 
16) Holmfeldt L, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013 ; 45 : 242-52.
PubMed
17) 熊本忠史ほか. 厚生労働省科学研究費補助金 (がん政策研究事業) 小児期に発症する遺伝性腫瘍に対するがんゲノム医療体制実装のための研究 リー・フラウメニ症候群の診療ガイドライン. 2020. http://jsht.umin.jp/news/download/2020032403.pdf
 
18) Moriyama T, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet 2016 ; 48 : 367-73.
PubMed

2章 急性リンパ性白血病 ( ALL )

P.30 掲載の参考文献
1) Kato M, et al. Prognostic impact or gained chromosomes in high-hyperdiploid childhood acute lymphoblastic leukaemia : a collaborative retrospective study of the Tokyo Children's Cancer Study Group and Japan Association of Childhood Leukaemia Study. Br J Haematol 2014 ; 166 : 295-8.
 
2) Paulsson K, et al. The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Nat Genet 2015 ; 47 : 672-6.
PubMed
3) McNeer JL, et al. Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia : A Report From Children's Oncology Group. J Clin Oncol 2019 ; 37 : 780-9.
 
4) Holmfeldt L, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013 ; 45 : 242-52.
PubMed
5) Harewood L, et al. Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia : a study of 20 cases. Leukemia 2003 ; 17 : 547-53.
PubMed
6) Harrison CJ, et al. An international study of intrachromosomal amplification of chromosome 21 (iAMP21) : cytogenetic characterization and outcome. Leukemia 2014 ; 28 : 1015-21.
 
7) Heerema NA, et al. Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies : a report from the children's oncology group. J Clin Oncol 2013 ; 31 : 3397-402.
 
8) Attarbaschi A, et al. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification or chromosome 21 : the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. J Clin Oncol 2008 ; 26 : 3046-50.
PubMed
9) Takahashi H, et al. Treatment outcome of children with acute lymphobalstic leukemia : the Tokyo Children's Cancer Study Group (TCCSG) Study L04-16. Int J Hematol 2018 ; 108 : 98-108.
 
10) Greaves MF, Wiemels J. Origins or chromosome translocations in childhood leukaemia. Nature Rev Cancer 2003 ; 3 : 639-49.
 
11) Gu Z, et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet 2019 ; 51 : 296-307.
PubMed
12) Meyer C, et al. The MLL recombinome of acute leukemias in 2013. Leukemia 2013 ; 27 : 2165-76.
PubMed
13) Den Boer ML, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome : a genome-wide classification study. Lancet Oncol 2009 ; 10 : 125-34.
PubMed
14) Roberts KG, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014 ; 371 : 1005-15.
PubMed
15) Seki M, et al. Recurrent SPI1 (PU. 1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia. Nat Genet 2017 ; 49 : 1274-81.
PubMed
16) Moriyama T, et al. Inherited genetic variation in childhood acute lymphoblastic leukemia. Blood 2015 ; 125 : 3988-95.
PubMed
17) Relling MV, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes : 2018 Update. Clin Pharmacol Ther 2019 ; 105 : 1095-105.
PubMed
18) Zhang J, et al. Germline Mutations in Predisposition Genes in Pediatric Cancer. N Engl J Med 2015 ; 373 : 2336-46.
PubMed
P.38 掲載の参考文献
1) Horibe K, et al. Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006-2010) : based on registry data from the Japanese Society of Pediatric Hematology. Int J Hematol 2013 ; 98 : 74-88.
PubMed
2) Pui CH, et al. Somatic and germline genomics in paediatric acute lymphoblastic leukaemia. Nat Rev Clin Oncol 2019 ; 16 : 227-40.
PubMed
3) Hunger S, et al. Acute Lymphoblastic Leukemia in Children. New Engl J Med 2015 ; 373 : 1541-52.
PubMed
4) Teachey DT, et al. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol 2019 ; 20 : e142-54.
 
5) Takahashi H, et al. Treatment outcome or children with acute lymphoblastic leukemia : the Tokyo Children's Cancer Study Group (TCCSG) Study L04-16. Int J Hematol 2018 ; 108 : 98-108.
 
6) Campana D, et al. Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia. Blood 2017 ; 129 : 1913-7.
PubMed
7) Vora A, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL2003) : a randomised controlled trial. Lancet Oncol 2013 ; 14 : 199-209.
 
8) Vora A, et al. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003) : a randomised controlled trial. Lancet Oncol 2014 ; 15 : 809-18.
 
9) Conter V, et al. Molecular response to treatment redifines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia : results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010 ; 115 : 3206-14.
PubMed
10) 日本小児血液・がん学会 (編). 小児白血病・リンパ腫ガイドライン 2016年版. 東京 : 金原出版 ; 2016.
 
11) Roberts KG, et al. Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL. Blood Adv 2017 ; 30 : 1657-71.
 
12) Hayakawa F, et al. Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol : a phase II study by the Japan Adult Leukemia Study Group. Blood Cancer J 2014 ; 4 : e252.
 
13) Teuffel O, et al. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia : a systematic review and meta-analysis. Leukemia 2011 ; 25 : 1232-8.
PubMed
14) Larsen EC, et al. Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia : A Report From Children's Oncology Group Study AALL0232. J Clin Oncol 2016 ; 34 : 2380-8.
 
15) Inaba H, et al. Immunotherapy in pediatric acute lymphoblastic leukemia. Cancer Metastasis Rev 2019 ; 38 : 595-610.
PubMed
16) Jeha S, et al. Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation : St Jude Total Therapy Study 16. J Clin Oncol 2019 ; 37 : 3377-91.
PubMed
17) Teachy DT, et al. Optimizing Therapy in the Modern Age : Differences in Length of Maintenance Therapy in Acute Lymphoblastic Leukemia. Blood 2021 ; 137 : 168-77.
PubMed
18) Kato M, et al. Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children. Leukemia 2017 ; 31 : 580-4.
PubMed
P.45 掲載の参考文献
1) Teachey DT, Pui C-H. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol 2019 ; 20 : e142-54.
 
2) Karrman K, et al. Pediatric T-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer 2017 ; 56 : 89-116.
PubMed
3) Liu Y, et al. The genomic landscape or pediatric and young adult T-lineage acute lymphoblastic leukema. Nat Genet 2017 ; 49 : 1211-8.
 
4) Schrappe M, et al. Late MRD response determines relapse risk overall and in Subsets of childhood T-cell ALL : results or the AIEOPBFM-ALL 2000 study. Blood 2011 ; 118 : 2077-84.
PubMed
5) Schrappe M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 2000 ; 14 : 2205-22.
 
6) Couslan-Smith E, et al. Early T-cell precursor leukaemia : a sub type of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009 ; 10 : 147-56.
 
7) Wood BL, et al. T-lymphoblastic Leukemia (T-ALL) Shows excellent outcome, lack of significance of the early Thymic precursor (ETP) Immunophenotype, and validation of the prognostic value of end-induction minimal residual disease (MRD) in Children's oncology group (COG) study AALL0434. Blood 2014 ; 124 : 1. meeting abstract.
 
8) Patrick K, et al. Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol 2014 ; 166 : 421-4.
 
9) Modvig S, et al. Minimal residual disease quantification by flow cytometry provides reliable risk statification in T-cell acute lymphoblastic leukemia. Leukemia 2019 ; 33 : 1324-36.
 
10) Moricke A, et al. Dexamethasone vs prednisone in induction treatment of pediatric ALL : results of the randomized trial AIEOP-BFM ALL 2000. Blood 2016 ; 127 : 2101-12.
PubMed
11) Synold TW, et al. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest 1994 ; 94 : 1996-2001.
PubMed
12) Asselin BL, et al. Effectivenessor high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma : a randomized study by the Children's Oncology Group (POG9404) Blood 2011 ; 118 : 874-83.
 
13) Winter SS, et al. Improved survival for children and young adults with T-lineage acute lymphoblastic Leukemia : results from the Children's oncology group AALL0434 methotrexate randomization. J Clin Oncol 2018 ; 36 : 2926-34.
 
14) Amylon MD, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma : a Pediatric Oncology Group study. Leukemia 1999 ; 13 : 335-42.
 
15) van der Sluis IM, et al. Consensus enert recommendations for identification and management or asparaginase hypersensitivity and silent inactivation. Haematologica 2016 ; 101 : 279-85.
PubMed
16) Berg SL, et al. Phase II study or Nelarabine (compound 506U78) in children and young adults with refractory T-cell malignanciecs : a report from the Children's oncology group. J Clin Oncol 2005 ; 23 : 3376-82.
 
17) Winter SS, et al. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia : Children's Oncology Group study AALL0434. Pediatr Blood Cancer 2015 ; 62 : 1176-83.
 
18) Dunsmore KP, et al. Children's Oncology Group AALL0434 : A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol 2020 ; 38 : 3282-93.
 
P.53 掲載の参考文献
1) Nowell PC, Discovery of the Philadelphia chromosome : a personal perspective. J Clin Invest 2007 ; 117 : 2033-5.
PubMed
2) Neuendorff NR, et al. BCR-ABL-positive acute myeloid leukemia : a new entity? Analysis of clinical and molecular features. Ann Hematol 2016 ; 95 : 1211-21.
PubMed
3) Faderl S, et al. The biology of chronic myeloid leukemia. N Engl J Med 1999 ; 341 : 164-72.
PubMed
4) Cimino G, et al. The role or BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia : a seven-year update of the GIMEMA 0496 trial. Haematologica 2006 ; 91 : 377-80.
 
5) Secker-Walker LM, et al. Philadelphia positive acute lymphoblastic leukemia in adults : age distribution, BCR breakpoint and prognostic significance. Leukemia 1991 ; 5 : 196-9.
PubMed
6) Verma D, et al. Chronic myeloid leukemia (CML) with P190 BCR-ABL : analysis of characteristics, outcomes, and prognostic significance.Blood 2009 ; 114 : 2232-5.
PubMed
7) Schenk TM, et al. Multilineagc involvement of Philadelphia chromosom e positive acute lymphoblastic leukemia. Leukemia 1998 ; 12 : 666-74.
 
8) Andolina JR, et al. How I treat childhood CML. Blood 2012 ; 119 : 1821-30.
 
9) Schultz KR, et al. Long-term follow-up of imatinibin pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia : Children's Oncology Group study AALL0031. Leukemia 2014 ; 28 : 1467-71.
 
10) Short NJ, et al. Poor outcomes associated with +der (22) t (9 ; 22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol 2017 ; 92 : 238-43.
 
11) Wassmann B, et al. Early prediction of response in patients with relapsed of refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib. Blood 2004 ; 103 : 1495-8.
PubMed
12) Conter V, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia : results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010 ; 115 : 3206-14.
PubMed
13) Cazzaniga G, et al. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR-ABL1 methodologies. Haematologica 2018 ; 103 : 107-15.
PubMed
14) Hovorkova L, et al. Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology. Blood 2017 ; 129 : 2771-81.
PubMed
15) Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006 ; 354 : 166-78.
PubMed
16) Arico M, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000 ; 342 : 998-1006.
PubMed
17) Schrappe M, et al. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia : good initial steroid response allows early prediction of a favorable treatment outcome. Blood 1998 ; 92 : 2730-41.
PubMed
18) Mori T, et al. Allogeneic bone marrow transplantation in first remission rescues children with Philadelphia chromosome-positive acute lymphoblastic leukemia : Tokyo Children's Cancer Study Group (TCCSG) studies L89-12 and L92-13. Med Pedialr Oncol 2001 ; 37 : 426-31.
 
19) Savage DG, Antman KH. Imatinib mesylate : a new oral targeted therapy. N Engl J Med 2002 ; 346 : 683-93.
PubMed
20) Druker BJ, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996 ; 2 : 561-6.
PubMed
21) Talpaz M, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006 ; 354 : 2531-41.
PubMed
22) Druker BJ, et al. Efficacy and safety or a specific inhibitor of the BCR-ABL tvrosine kinase in chronic myeloid leukemia. N Engl J Med 2001 ; 344 : 1031-7.
 
23) Thomas DA, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004 ; 103 : 4396-407.
PubMed
24) Yanada M, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia : a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006 ; 24 : 460-6.
 
25) Biondi A, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL) : a randomised, open-label, intergroup study. Lancet Oncol 2012 ; 13 : 936-45.
PubMed
26) Biondi A, et al. Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010) : a prospective, intergroup, open-label, singel-arm clinical trial. Lancet Haematol 2018 ; 5 : e641- 52.
 
27) Manabe A, et al. Imatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia : results from Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study Ph (+) ALL04. Cancer Medicine 2015 ; 4 : 682-9.
 
28) Foa R, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-ppositive acute lymphoblastic leukemia. Blood 2011 ; 118 : 6521-8.
 
29) Slayton WB, et al. Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia : Results of Children's Oncology Group Trial AALL0622. J Clin Oncol 2018 ; 36 : 2306-14.
 
30) Hunger SP, et al. CA180-372 : An International Collaborative Phase 2 Trial or Dasatinib and Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL). Blood 2017 ; 130 (Supplement 1) : 98.
 
31) Shima H, et al. Distinct impact of imatinib on growth at prepubertal and pubertal ages or children with chronic myeloid leukemia. J Pediatr 2011 ; 159 : 676-81.
PubMed
32) Mahon FX, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years : the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010 ; 11 : 1029-35.
PubMed
33) Giebel S, et al. Use or tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia : a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer 2016 ; 122 : 2941-51.
 
34) Olivieri A, et al. Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. Blood 2013 ; 122 : 4111-8.
PubMed
35) Sanchez-Ortega I, et al. Dasatinib as salvage therapy for steroid refractory and imatinib resistant or intolerant sclerotic chronic graft-versus-host disease. Biol Blood Marrow Transplant 2012 ; 18 : 318-23.
 
36) Hirase C, et al. Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin : possible clinical application of mTOR inhibitor. Leuk Res 2009 ; 33 : 450-9.
PubMed
37) Nemoto A, et al. Specific antileukemic activity of PD0332991, a CDK4/6 inhibitor, Philadelphia chromosome-positive lymphoid leukemia. Mol Cancer Ther 2016 ; 15 : 94-105.
PubMed
38) Tanaka A, et al. Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells. J Exp Med 2019 ; 217.
 
P.60 掲載の参考文献
1) Swerdlow SH, et al (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed., Revised ed. Lyon : International Agency for Research on Cancer ; 2017.
 
2) Horibe K, et al. Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006-2010) : based on registry data from the the Japanese Society of Pediatric Hematology. Int J Hematol 2013 ; 98 : 74-88.
PubMed
3) Johnston W, et al. Relationship between Plasmodium falciparum malaria prevalence, genetic diversity and endemic Burkitt lymphoma in Malawi. Sci Rep2014 ; 4 : 3741.
PubMed
4) Abate F, et al. Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma. PLoS Pathog 2015 ; 11 : e1005158.
PubMed
5) Sander S, et al. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell 2012 ; 22 : 167-79.
PubMed
6) Dittmer D. Not like a wrecking ball : EBV fine-tunes MYC lymphomagenesis. Blood 2014 ; 123 : 460-1.
 
7) Campo E. New pathogenic mechanisms in Burkitt lymphoma. Nat Genet 2012 ; 44 : 1288-9.
PubMed
8) Love C, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012 ; 44 : 1321-5.
PubMed
9) Richter J, et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 2012 ; 44 : 1316-20.
PubMed
10) Rosolen A, et al. Revised International Pediatric Non-Hodgkin Lymphoma Staging System. JCO 2015 ; 33 : 2112-8.
PubMed
11) Rodig S, et al. Characteristic expression patterns or TCL1, CD38, and CD44 identify aggressive lymphomas harboring a MYC translocation. Am J Surg Pathol 2008 ; 32 : 113-22.
 
12) Navid F, et al. Acule lymphoblastic leukemia with the (8 ; 14) (q24 ; q32) translocation and FAB L3 morphology associated with a B-precursor immunophenotype : the Pediatric Oncology Group experience. Leukemia 1999 ; 13 : 135-41.
 
13) Rciter A, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy : A report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 1999 ; 94 : 3294-306.
PubMed
14) Tsurusawa M, et al. Improved treatment results of children with B-cell non-Hodgkin lymphoma : a report from the Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL03 study. Pediat Blood Cancer 2014 ; 61 : 1215-21.
 
15) Patte C, et al. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol : highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001 ; 97 : 3370-9.
 
16) Patte C, et al. Results or the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents : it is possible to reduce treatment for the early responding patients. Blood 2007 ; 109 : 2773-80.
 
17) Cairo M, et al. Results of a randomized international study or high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007 ; 109 : 2736-43.
 
18) Minard-Colin V, et al. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. NEJM 2020 ; 383 : 2207-19.
 
P.67 掲載の参考文献
1) Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med 2015 ; 373 : 1541-52.
PubMed
2) Wood WA, Lee SJ. Malignant hematologic disease in adolescents and young adults. Blood 2011 ; 117 : 5803-15.
 
3) Boissel N, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003 ; 21 : 774-80.
 
4) Ramanujachar R, et al. Adolescents with acute lymphoblastic leukaemia : outcome on UK national paediatric (ALL97) and adult (UKALL XII/E2993) trials. Pediatr Blood Cancer 2007 ; 48 : 254-61.
 
5) Pui CH, et al. Pediatric acute lymphoblastic leukemia : where are we going and how do we get There? Blood 2012 ; 120 : 1165-74.
PubMed
6) Pui CH, et al. Biology, risk stratification, and therapy of pediatric acute leukemias : An update. J Clin Oncol 2011 ; 29 : 551-65.
PubMed
7) Mullighan CG, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009 ; 360 : 470-80.
PubMed
8) Den Boer M, et al. A subtype of childhood acute lymphoblastic leukemia with poor treatment outcome : a genome-wide classification study. Lancet Oncol 2009 ; 10 : 125-34.
 
9) Roberts KG. Genetics and prognosis of ALL in children vs adults. Hematology Am Soc Hematol Educ Program 2018 ; 2018 : 137-45.
PubMed
10) Roberts KG, et al. High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults. J Clin Oncol 2017 ; 35 : 394-401.
PubMed
11) Yasuda T, et al. Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat Genet 2016 ; 48 : 569-74. [published correction appears in Nat Genet 2016 ; 48 : 1591]
 
12) Boissel N, Baruchel A. Acute lymphoblastic leukemia in adolescent and young adults : treat as adults or as children? Blood 2018 ; 132 : 351-61.
 
13) Pui CH, et al. Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol 2011 ; 29 : 386-91.
PubMed
14) Ribera JM, et al. Comparison of the results of the treatment of adolescents and young adults with standard risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol 2008 ; 26 : 1843-9.
 
15) Hayakawa F, et al ; Japan Adult Leukemia Study Group (JALSG). Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol : a phase II study by the Japan Adult Leukemia Study Group. Blood Cancer J 2014 ; 4 : e252.
 
16) Toft N, et al. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia 2018 ; 32 : 606-15.
PubMed
P.72 掲載の参考文献
1) Ghaderi S, et al. Cancer in childhood, adolescence, and young adults : a population-based study of changes in risk of cancer death during four decades in Norway. Cancer Causes Control 2012 ; 23 : 1297-305.
 
2) Mullighan CG, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008 ; 322 : 1377-80.
PubMed
3) Waanders E, et al. Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia. Blood Cancer Discov 2020 ; 1 : 96-111.
PubMed
4) Irving J, et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood 2014 ; 124 : 3420-30.
PubMed
5) Oshima K, et al. Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2016 ; 113 : 11306-11.
PubMed
6) Jain R, et al. Unusual sites of relapse in pre-B acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2014 ; 36 : e506-8.
PubMed
7) Nguyen K, et al. Factorsluencing survival after relapse from acute lymphoblastic leukemia : a Children's Oncology Group Study. Leukemia 2008 ; 22 : 2142-50.
 
8) Krentz S, et al. Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia. Leukemia 2013 ; 27 : 295-304.
PubMed
9) Eckert C, et al. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol 2013 ; 31 : 2736-42.
 
10) Parker C, et al. Effect or mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALLR3) : an open-label randomised trial. Lancet 2010 ; 376 : 2009-17.
 
11) Hagedorn N, et al. Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia : a more precise definition of "isolated" and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM study group. Blood 2007 ; 110 : 4022-9.
 
12) Barredo JC, et al. Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation : a pediatric oncology group study. J Clin Oncol 2006 ; 24 : 3142-9.
 
13) Barredo JC, et al. Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation : A Children's Oncology Group. study. Pediatr Blood Cancer 2018 ; 65 : e26928.
 
14) Masurekar AN, et al. Outcome of central nervous system relapses in childhood acute lymphoblastic leukaemia--prospective open cohort analyses of the ALLR3 trial. PLoS One 2014 ; 9 : e108107.
PubMed
15) Paganin M, et al. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia. Leukemia 2008 ; 22 : 2193-200.
PubMed
P.80 掲載の参考文献
1) Benjamin JE, Stein AS. The role or blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemla. Ther Adv Hematol 2016 ; 7 : 142-56.
PubMed
2) von Stackelberg A, et al. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. J Clin Oncol 2016 ; 34 : 4381-9.
PubMed
3) Parker C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3) : an open-label randomised trial. Lancet 2010 ; 376 : 2009-17.
PubMed
4) Brown PA, et al. A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab : A Report from Children's Oncology Group Study AALL1331. Blood 2019 ; 134 (Supplement 2).
 
5) Gore L, et al. Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Blood Cancer J 2018 ; 8 : 80.
PubMed
6) Wolfl M, et al. Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in MLL-rearranged infant ALL> Blood Adv 2018 ; 2 : 1382-5.
PubMed
7) 中沢洋三. 血液腫瘍に対するCAR-T療法. 臨床血液 2019 ; 60 : 1351-7.
 
8) Maude SL, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med 2018 ; 378 : 439-48.
 
9) Majzner RG, Mackall CL. Tumor Antigen Escape from CAR T-Cell Therapy. Cancer Discov 2018 ; 8 : 1219-26.
PubMed
10) Orlando EJ, et al. Genetic mechanisms or target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nal Med 2018 ; 24 : 1504-6.
 
11) de Vries JF, et al. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia 2012 ; 26 : 255-64.
PubMed
12) Bhojwani D, et al. Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Leukemia 2019 ; 33 : 884-92.
PubMed
13) Kantarjian H, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia : a phase 2 study. Lancet Oncol 2012 ; 13 : 403-11.
PubMed
14) Kantarjian HM, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med 2016 ; 375 : 740-53.
PubMed

3章 急性骨髄性白血病 ( AML )

P.89 掲載の参考文献
1) Shiba N, et al. Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia. Blood Adv 2019 ; 3 : 3157-69.
PubMed
2) Bolouri H, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med 2018 ; 24 : 103-12.
PubMed
3) Panagopoulos I, et al. Fusion of the FUS gene with ERG in acute myeloid leukemia with t (16 ; 21) (p11 ; q22). Genes Chromosomes Cancer 1994 ; 11 : 256-62.
 
4) Hollink IH, et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood 2011 ; 118 : 3645-56.
PubMed
5) Kondo M, et al. Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Med Pediatr Oncol 1999 ; 33 : 525-9.
PubMed
6) Hollink IH, et al. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia 2009 ; 23 : 262-70.
PubMed
7) Yamato G, et al. RUNX1 mutations in pediatric acute myeloid leukemia are associated with distinct genetic features and an inferior prognosis. Blood 2018 ; 131 : 2266-70.
 
8) Shimada A, et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t (8 ; 21) : a study of the Japanese Childhood AML Cooperative Study Group. Blood 2006 ; 107 : 1806-9.
 
9) Tokumasu M, et al. Adverse prognostic impact of KIT mutations in childhood CBF-AML : the results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial. Leukemia 2015 ; 29 : 2438-41.
 
10) Shiba N, et al. High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1 : the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial. Br J Haematol 2016 ; 172 : 581-91.
 
11) Shiba N, et al. Mutations of the GATA2 and CEBPA genes in paediatric acute myeloid leukaemia. Br J Haematol 2014 ; 164 : 142-5.
PubMed
12) Matsuo H, et al. Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia : a report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Blood Cancer J 2014 ; 4 : e226.
 
13) Faber ZJ, et al. The genomic landscape of core-binding factor acute myeloid leukemias. Nat Genet 2016 ; 48 : 1551-6.
PubMed
14) Hara Y, et al. Patients aged less than 3 years with acute myeloid leukaemia characterize a molecularly and clinically distinct subgroup. Br J Haematol 2020 ; 188 : 528-39.
PubMed
15) Matsuo H, et al. EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia. Haematologica 2014 ; 99 : e225-7.
PubMed
16) Gruber TA, et al. An Inv (16) (p13.3 q24.3) -encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype or pediatric acute megakaryoblastic leukemia. Cancer Cell 2012 ; 22 : 683-97.
PubMed
17) Shiba N, et al. NUP98-NSD1 gene fusion and its related gene expression signature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia. Genes Chromosomes Cancer 2013 ; 52 : 683-93.
PubMed
18) Jo A, et al. Age-associated difference in gene expression of paediatric acute myelomonocytic lineage leukaemia (FAB M4 and M5 subtypes) and its correlation with prognosis. Br J Haematol 2009 ; 144 : 917-29.
PubMed
19) Patel JP, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012 ; 366 : 1079-89.
PubMed
20) Kayser S, et al. Management of patients with acute promyelocytic leukemia. Leukemia 2018 ; 32 : 1277-94.
PubMed
21) Osumi T, et al. Recurrent RARB Translocations in Acute Promyelocytic Leukemia Lacking RARA Translocation. Cancer Res 2018 ; 78 : 4452-8.
PubMed
22) Tianhui L, et al. Identification of novel recurrent CPSF6-RARG fusions in acute myeloid leukemia resembling acute promyelocytic leukemia. Blood 2018 ; 131 : 1870-3.
 
P.98 掲載の参考文献
1) Swerdlow SH, et al (eds). WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th ed., Revised ed. Lyon : International Agency for Research on Cancer ; 2017.
 
2) Horibe K, et al. Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006-2010) : based on registry data from the Japanese Society of Pediatric Hematology. Int J Hematol 2013 ; 98 : 74-88.
PubMed
3) Creutzig U, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents : recommendations from an international expert panel. Blood 2012 ; 120 : 3187-205.
 
4) Inaba H, et al. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol 2012 ; 30 : 3625-32.
PubMed
5) Scott BL, et al. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acue Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol 2017 ; 35 : 1154-61.
 
6) Pession A, et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood 2013 ; 122 : 170-8.
PubMed
7) Creutzig U, et al. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia : results from Study AML-BFM 2004. Blood 2013 ; 122 : 37-43.
PubMed
8) Rasche M, et al. Successes and challenges in the treatment of pediatric acute myeloid leukemia : a retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia 2018 ; 32 : 2167-77.
PubMed
9) Gamis AS, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute by reducing relapse risk : results from the randomized phase III Children's Oncology Group trial AAML0531. J Clin Oncol 2014 ; 32 : 3021-32.
 
10) Aplenc R, et al. Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes : a report from the Children's Oncology Group. Haematologica 2020 ; 105 : 1879-86.
 
11) Tomizawa D, et al. Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children. Leukemia 2013 ; 27 : 2413-6.
PubMed
12) Hasegawa D, et al. Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-biniding factors : A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). Pediatr Blood Cancer 2020 ; 67 : e28692.
 
13) Gibson BE, et al. Results of a randomized trial in children with Acute Myeloid Leukaemia : medical research council AML12 trial. Br J Haematol 2011 ; 155 : 366-76.
PubMed
14) Abrahamsson J, et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol 2011 ; 29 : 310-5.
 
15) Hasle H, et al. Gemtuzumab ozogamicin as post-consolidation therapy does not prevent relapse in children with AML : results from NOPHO-AML 2004. Blood 2012 ; 120 : 978-84.
 
16) Rubnitz JE, et al. Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia : The AML08 Multicenter, Randomized Phase III Trial. J Clin Oncol 2019 ; 37 : 2072-81.
PubMed
17) De Moerloose B, et al. Responso-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission : Results from protocol DB AML-01. Pediatr Blood Cancer 2019 ; 66 : e27605.
 
18) Petit A, et al. Maintenance Therapy with Interleukin-2 for Childhood AML : Results of ELAM02 Phase III Randomized Trial. Hemasphere2018 ; 2 : e159.
PubMed
P.106 掲載の参考文献
1) Arber DA, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016 ; 127 : 2391-405.
 
2) Sanz MA, et al. Management of acute promyelocytic leukemia : updated recommendations from an expert panel of the European LeukemiaNet. Blood 2019 ; 133 : 1630-43.
 
3) Taga T, et al. Acute myeloid leukemia in children : Current status and future directions. Pediatr Int 2016 ; 58 : 71-80.
PubMed
4) Sanz MA, et al. Advances in the management of coagulopathy in acute promyelocytic leukemia. Thromb Res 2020 ; 191 Suppl 1 : S63-7.
 
5) 朝倉英策. 腫瘍と凝固障害. 日小児血がん会誌 2013 ; 50 : 316-21.
Medical*Online
6) Takahashi H, et al. High event-free survival rate with minimum-dose-anthracycline treatment in childhood acute promyelocytic leukaemia : A nationwide prospective study by the Japanese Paediatric Leukaemia/Lymphoma Study Group. Brit J Haematol 2016 ; 174 : 437-43.
 
7) Geoffroy MC, et al. Classic and variants APLs, as viewed from a therapy response. Cancers (Basel) 2020 ; 12 : 967.
PubMed
8) 高見昭良, ほか. 科学的根拠に基づいた血小板製剤の使用ガイドライン 2019年改訂版. 日輸血細胞治療会誌 2019 ; 65 : 544-61.
Medical*Online
9) Rashidi A, et al. Thrombosis in acute promyelocytic leukemia. Thromb Res 2013 ; 131 : 281-9.
PubMed
10) Montesinos P, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy : characteristics, outcome, and prognostic factors. Blood 2009 ; 113 : 775-83.
PubMed
11) Testi AM, et al. Risk-adapted treatment of acute promyelocytic leukemia : results from the International Consortium for Childhood APL. Blood 2018 ; 132 : 405-12.
 
12) Esteve J, et al. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trams retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99) : benefit of an early intervention. Leukemia 2007 ; 21 : 446-52.
 
13) Chen SJ, et al. From an old remedy to a magic bullet : molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood 2011 ; 117 : 6425-37.
PubMed
14) Lo-Coco F, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013 ; 369 : 111-21.
PubMed
15) Kutny MA, et al. Arsenic trioxide consolidation allows anthracycline dose reduction for pediatric patients with acute promyelocytic leukemia : Report from the Children's Oncology Group phase III historically controlled trial AAML0631. J Clin Oncol 2017 ; 35 : 3021-9.
 
16) Zhang L, et al. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide : a randomized controlled trial. BMC Cancer 2018 ; 18 : 374.
PubMed
17) Abla O, et al. Management of relapsed and refractory childhood acute promyelocytic leukaemia : recommendations from an international expert panel. Br J Haematol 2016 ; 175 : 588-601.
 
18) Yanada M, et al. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood 2013 ; 121 : 3095-102.
PubMed
P.112 掲載の参考文献
1) Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol 2000 ; 110 : 512-24.
PubMed
2) Hasle H, et al. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000 ; 355 : 165-9.
PubMed
3) Xu G, et al. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood 2003 ; 102 : 2960-8.
PubMed
4) Banno K, et al. Systematic Cellular Disease Models Reveal Synergistic Interaction of Trisomy 21 and GATA1 Mutations in Hematopoietic Abnormalities. Cell Rep 2016 ; 15 : 1228-41.
PubMed
5) Toki T, et al. Naturally occurring oncogenic GATA1 mutants with internal deletions in transient abnormal myelopoiesis in Down syndrome. Blood 2013 ; 121 : 3181-4.
PubMed
6) Terui K, et al. Highly sensitive detection of GATA1 mutations in patients with myeloid leukemia associated with Down syndrome by combining Sanger and targeted next generation sequencing. Genes Chromosomes Cancer 2020 ; 59 : 160-7.
PubMed
7) Yoshida K, et al. The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet 2013 ; 45 : 1293-9.
PubMed
8) Muramatsu H, et al. Risk factors for early death in neonates with Down syndrome and transient leukaemia. Br J Haematol 2008 ; 142 : 610-5.
PubMed
9) Arber DA, et al. Myeloid proliferations associated with Down syndrome. In : Swerdlow SH, et al (eds). WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th ed., Revised ed. Lyon : International Agency for Research on Cancer ; 2017. p. 169-71.
 
10) Taga T, et al. Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome : A Nationwide Prospective Study in Japan. Pediatr Blood Cancer 2016 ; 63 : 248-54.
PubMed
11) Taga T, et al. Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with Down syndrome. Blood 2012 ; 120 : 1810-5.
PubMed
12) Scheer C, et al. Hematologic Response to Vorinostat Treatment in Relapsed Myeloid Leukemia of Down Syndrome. Pediatr Blood Cancer 2016 ; 63 : 1677-9.
PubMed
13) Uemura S, et al. Effective response to azacitidine in a child with a second relapse of myeloid leukemia associated with Down syndrome after bone marrow transplantation. Pediatr Blood Cancer 2018 ; 65 : e27414.
 
14) Flasinski M, et al. Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome : TMD Prevention 2007 study. Blood Adv 2018 ; 2 : 1532-40.
PubMed
P.118 掲載の参考文献
1) Tsukimoto I, et al. Risk-stratified therapy and the intensive use of AraC improves the outcome in childhood acute myeloid leukemia : the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol 2009 ; 27 : 4007-13.
 
2) Shimada A, et al. Tandem duplications of MLL and FLT3 are correlated with poor prognoses in pediatric acute myeloid leukemia : a study of the Japanese childhood AML Cooperative Study Group. Pediatr Blood Cancer 2008 ; 50 : 264-9.
 
3) Shimada A, et al. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia : results from the JPLSG AML-05 study. Int J Hematol 2018 ; 107 : 586-95.
PubMed
4) Stone RM, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med 2017 ; 377 : 454-64.
PubMed
5) Perl AE, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med 2019 ; 381 : 1728-40.
 
6) Altman JK, et al. Phase I study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. Am J Hematol 2018 ; 93 : 213-21.
 
7) Shimada A, et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t (8 ; 21) : a study of the Japanese Childhood AML Cooperative Study Group. Blood 2006 ; 107 : 1806-9.
 
8) Tokumasu M, et al. Adverse prognostic impact of KIT mutations in childhood CBF-AML : the results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial. Leukemia 2015 ; 29 : 2438-41.
 
9) Marcucci G, et al. Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia : CALGB 10801. Blood Adv 2020 ; 4 : 696-705.
PubMed
10) Stein EM, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 2017 ; 130 : 722-31.
 
11) DiNardo CD, et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med 2018 ; 378 : 2386-98.
PubMed
12) Gamis AS, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk : results from the randomized phase III Children's Oncology Group trial AAML0531. J Clin Oncol 2014 ; 32 : 3021-32.
 
13) Lancet Je, et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol 2018 ; 36 : 2684-92.
PubMed
14) Welch JS, et al. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med 2016 ; 375 : 2023-36.
PubMed
15) 2019 ASH late breaking abstract. https://www.ashclinicalnews.org/on-location/ash-annual-meeting/quazar-oral-azacitidine-maintenance-improves-survival-transplant-ineligible-aml/
 
16) Norsworthy KJ, et al. FDA Approval Summary : Glasdegib for Newly Diagnosed Acute Myeloid Leukemia. Clin Cancer Res 2019 ; 25 : 6021-5.
PubMed
17) Sarno F, et al. DOT1L : a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment. Epigenetics 2020 ; 15 : 439-53.
PubMed
18) McCalmont H, et al. Efficacy of combined CDK9/BET inhibition in preclinical models of MLL-rearranged acute leukemia. Blood Adv 2020 ; 4 : 296-300.
PubMed
19) DiNardo CD, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med 2020 ; 383 : 617-29.
PubMed

4章 乳児急性リンパ性白血病 ( 乳児ALL )

P.127 掲載の参考文献
1) Horibe K, et al. Incidence and survival rates or hematological malignancies in. Japanese children and adolescenls (2006-2010) : based on registry data from the Japanese Society of Pediatric Hematology. Int J Hematol 2013 ; 98 : 74-88.
 
2) Brown P. Treatment of infant leukemias : challenge and promise. Hematology Am Soc Hematol Educ Program. 2013 ; 2013 : 596-600.
PubMed
3) Mann G, et al. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL) -rearranged acute lymphoblastic leukemia : results from the Interfant-99 Study. Blood 2010 ; 116 : 2644-50.
 
4) Pieters R, et al. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol : Results From an International Phase III Randomized Study. J Clin Oncol 2019 ; 37 : 2246-56.
PubMed
5) Sorensen PH, et al. Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes. J Clin Invest 1994 ; 93 : 429-37.
PubMed
6) Pui CH, et al. Biology and treatment of infant leukemias. Leukemia 1995 ; 9 : 762-9.
PubMed
7) Hilden JM, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants : report on CCG 1953 from the Children's Oncology Group. Blood 2006 ; 108 : 441-51.
 
8) Stasik C, et al. Infant acute lymphoblastic leukemia with t (11 ; 16) (q23 ; p13.3) and lineage switch into acute monoblastic leukemia. Cancer Genet Cytogenet 2006 ; 168 : 146-9.
 
9) Rayes A, et al. Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy. Pediat Blood Cancer 2016 ; 63 : 1113-5.
 
10) Yokoyama A, Cleary ML. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 2008 ; 14 : 36-46.
PubMed
11) Winters AC, Gernt KM. Mll-Rearranged Leukemias-An Update on Science and Clinical Approaches. Front Pediatr 2017 ; 5 : 4.
 
12) Pfister SC, et al. SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability. Cell Rep 2014 ; 7 : 2006-18.
 
13) Risner LE, et al. Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia. J Biol Chem 2013 ; 288 : 29901-10.
PubMed
14) Milne TA, et al. Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Mol Cell 2010 ; 38 : 853-63.
 
15) Yokoyama A, et al. Proteolytically cleavd MLL subunits are susceptible to distinct degradation pathways. J Cell Sci 2011 ; 124 : 2208-19.
PubMed
16) Jude CD, et al. Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. Cell Stem Cell 2007 ; 1 : 324-37.
PubMed
17) Mishra BP, et al. The histone methyltransferase activity of MLL1 is dispensable for hematopoiesis and leukemogenesis. Cell Rep 2014 ; 7 : 1239-47.
PubMed
18) Macrini CM, et al. MLL AT-hook sequence is strongly conserved in infant acute leukemia with or without MLL gene rearrangement. Leukemia 2003 ; 17 : 1432-3.
PubMed
19) Corral J, et al. An MI1-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice : a method to create fusion oncogenes. Cell 1996 ; 85 : 853-61.
 
20) Hein D, et al. Insights into the prenatal origin of childhood acute lymphoblastic leukemia. Cancer Metastasis Rev 2020 ; 39 : 161-71.
PubMed
21) Meyer C, et al. The MLL recombinome of acute leukemias in 2013. Leukemia 2013 ; 27 : 2165-76.
PubMed
22) Meyer C, et al. The MLL recombinome of acute leukemias in 2017. Leukemia 2018 ; 32 : 273-84.
PubMed
23) Steinhilber D, Marschalek R. How to effectively treat acute leukemia patients bearing MLL-rearrangements? Biochem Pharmacol 2018 ; 147 : 183-90.
PubMed
24) Wu T, et al. Brd4's Bromodomains Mediate Histone H3 Acetylation and Chromatin Remodeling in Pluripotent Cells through P300 and Brg1. Cell Rep 2018 ; 25 : 1756-71.
PubMed
25) Bitoun E, et al. The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum Mol Genet 2007 ; 16 : 92-106.
PubMed
26) Yokoyama A. Molecular mechanisms of MLL-associated leukemia. Int J Hematol 2015 ; 101 : 352-61.
PubMed
27) Bernt KM, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011 ; 20 : 66-78.
PubMed
28) Krivtsov AV, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006 ; 442 : 818-22.
PubMed
29) Somervaille TC, Cleary ML. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 2006 ; 10 : 257-68.
PubMed
30) Kroon E, et al. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meisla but not Pbx1b. EMBO J 1998 ; 17 : 3714-25.
 
31) Andersson AK, et al. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet 2015 ; 47 : 330-7.
PubMed
32) Van der Velden VH, et al. Prognostic significance of minimal residual disease in infants within the Interfant-99 protocol. Leukemia 2009 ; 23 : 1073-9.
PubMed
33) Kosaka Y, et al. Infant acute lymphoblastic leukemia with MLL gene rearrangements : outcome following intensive chemotherapy and hematopoietic stem cell transplantation. Blood 2004 ; 104 : 3527-34.
PubMed
34) Koh K, et al. Early use of allogeneic hematopoietic stem cell transplantation for infants with MLL gene-rearrangement-positive acute lymphoblastic leukemia. Leukemia 2015 ; 29 : 290-6.
PubMed
35) Pieters R, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99) : an observational study and a multicentre randomised trial. Lancet 2007 ; 370 : 240-50.
 
36) Tomizawa D, et al. A risk-stratified therapy for infants with acute lymphoblastic leukemia : a report from the JPLSG MLL-10 trial. Blood 2020 ; 136 : 1813-23.
PubMed
37) Brown P, et al. How I treat infant leukemia. Blood 2019 ; 133 : 205-14.
 
P.134 掲載の参考文献
1) Horibe K, et al. Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006-2010) : based on registry data from the Japanese Society of Pediatric Hematology. Int J Hematol H2013 ; 98 : 74-88.
 
2) Tomizawa D. Recent progress in the treatment of infant acute lymphoblastic leukemia. Pediatr Int 2015 ; 57 : 811-9.
PubMed
3) Pui DH, et al. Biology and treatment of infant leukemias. Leukemia 1995 ; 9 : 762-9.
 
4) Biondi A, et al. Biological and therapeutic aspects of infant leukemia. Blood 2000 ; 96 : 24-33.
PubMed
5) Meyer C, et al. The MLL recombinome of acute leukemias in 2017. Leukemia 2018 ; 32 : 273-84.
PubMed
6) Brown P, et al. How I treat infant leukemia. Blood 2009 ; 133 : 205-14.
 
7) Ramakers-van Woerden NL, et al. In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to agg, MLL rearrangements and immunophenotype. Leukemia 2004 ; 18 : 521-9.
 
8) Nagayama J, et al. Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone : results from the Japan Infant Leukemia Study Group. Blood 2006 ; 107 : 4663-5.
 
9) Kosaka Y, et al. Infant acute lymphoblastic leukemia with MLL gene rearrangements : outcome following intensive chemotherapy and hematopoietic stem cell transplantation. Blood 2004 ; 104 : 3527-34. -directed treatment of infant acute lymphoblastic leukaemia based on early assessment of MLL gene status : results of the Japan Infant Leukaemia Study (MLL96). Br J Haematol 2002 ; 118 : 999-1010.
 
11) Koh K, et al. Early use of allogeneic hematopoietic stem cell transplantation for infants with MLL gene-rearrangement-positive acute lymphoblastic leukemia. Leukemia 2015 ; 29 : 290-6.
PubMed
12) Tomizawa D, et al. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects : a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia 2007 ; 21 : 2258-63.
 
13) Tomizawa D, et al. A risk-stratified therapy for infants with acute lymphoblastic leukemia : a report from the JPLSG MLL-10 trial. Blood 2020 ; 136 : 1813-23.
PubMed
14) Pieters R, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99) : an obsservational study and a multicentre randomised trial. Lancet 2007 ; 370 : 240-50.
 
15) Pieters R, et al. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol : Results From an International Phase III Randomized Study. J Clin Oncol 2019 ; 37 : 2246-56.
PubMed
16) Hilden JM, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants : report on CCG 1953 from the Children's Oncology Group. Blood 2006 ; 108 : 441-51.
 
18) Brown P, et al. Abstracts From the 48th Congress of the International Society of Paediatric Oncology (SIOP) Dublin, Ireland October 19-22, 2016. Pediatr Blood Cancer 2016 ; 63 Suppl 3 : S5-321.
 
19) Van der Velden VHJ, et al. Prognostic significance of mininml residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia 2009 ; 23 : 1073-9.
PubMed
20) Rayeres A, et al. Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy. Pediatr Blood Cancer 2016 ; 63 : 1113-5.
PubMed
21) Stumple DJ, et al. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. Blood 2011 ; 114 : 5490-8.
 
22) Stumpel DJ, et al. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia. Eur J Cancer 2015 ; 51 : 2008-21.
PubMed
Dreyer ZE, et al. Intensified chemotherapy without SCT in infant ALL : results from COG P9407 (Cohort 3). Pediatr Blood Cancer 2015 ; 62 : 419-26.
PubMed
P.139 掲載の参考文献
1) Cruickshank MN, et al. Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin. Leukemia 2017 ; 31 : 40-50.
PubMed
2) Stumpel DJ, et al. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia. Eur J Cancer 2015 ; 51 : 2008-21.
PubMed
3) Fournier E, et al. Increased risk or adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in KMT2A-rearranged acute lymphoblastic leukemia : a case report and review of the literature. Leuk Lymphoma 2019 ; 60 : 1827-30.
 
4) Gardner R, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 2016 ; 127 : 2406-10.
PubMed
5) Bernt KM, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOTIL. Cancer Cell 2011 ; 20 : 66-78.
 
6) Liu H, et al. Proleasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4. Cancer Cell 2014 ; 25 : 530-42.
 
7) McGinty RK, et al. Chemically ubiquitylated histone H2B stimulates hDot1L-medialed intranucleosomal methylation. Nature 2008 ; 453 : 812-6.
 
8) Cooper TM, et al. A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia : A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) study Clin Cancer Res 2016 ; 22 : 4014-22.
PubMed
9) Klossowski S, et al. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models or leukemia. J Clin Invest 2020 ; 130 : 981-97.
PubMed
10) Krivtsov AV, et al. A Menin-MLL inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. Cancer Cell 2019 ; 36 : 660-73.e11.
 
11) Khaw SL, et al. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood 2016 ; 128 : 1382-95.
PubMed
12) Loftus JP, et al. Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia. Haematologica 2020. doi : 10.3324/haematol.2019.241729. Online ahead of print.
 
13) Andersson AK, et al. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet 2015 ; 47 : 330-7.
PubMed
14) Esposito MT. The Imapact of PI3-kinase/RAS Pathway Cooperating Mutations in the Evolution of KMT2A-rearranged Leukemia. Hemasphere 2019 ; 3 : e195.
 
15) Sykes DB, et al. Inhibition or Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia. Cell 2016 ; 167 : 171-86.e15.
 
16) Baker A, et al. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models or MLL-Rearranged Acute Myeloid Leukemia. Cancer Res 2016 ; 76 : 1158-69.
PubMed
17) Placke T, et al. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood 2014 ; 124 : 13-23.
PubMed

5章 慢性骨髄性白血病 ( CML )

P.148 掲載の参考文献
1) Bose S, et al. The presence of typica l and atypical BCR-ABL fusion genes in leukocytes of normal individuals : Biologic significance and implications for the assessment of minimal residual disease. Blood 1998 ; 92 : 3362-7.
 
2) Gunes AM, et al. Features and outcome of chronic myeloid leukemia at very young age : Data from the International Pediatric Chronic Myeloid Leukemia registry. Pediatr Blood Cancer 2021 ; 68 : e28706.
 
3) Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev 2005 ; 5 : 172-83.
PubMed
4) O'Brien SG, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003 ; 348 : 994-1004.
PubMed
5) Kurosawa H, et al. Leukostasis in Children and Adolescents with Chronic Myeloid Leukemia : Japanese Pediatric Leukemia/Lymphoma Study Group. Pediatr Blood Cancer 2016 ; 63 : 406-11.
 
6) Krumbholz M, et al. Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia. Genes Chromosom Cancer 2012 ; 51 : 1045-53.
PubMed
7) Krumbholz M, et al. Copy Number Variations and IKZF1 Mutations In Pediatric CML. Blood 2013 ; 122 : 1473.
 
8) Adler R, et al. Correlation oF BCR/ABL transcript variants with patients' characteristics in childhood chronic myeloid leukaemia. Eur J Haematol 2009 ; 82 : 112-8.
PubMed
9) Lucas CM, et al. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. Haematologica 2009 ; 94 : 1362-7.
PubMed
10) Suttorp M, et al. Impact of the type of the BCR-ABL fusion transcript on the molecular response in pediatric patients with chronic myeloid leukemia. Haematologica 2010 ; 95 : 852-3.
PubMed
11) Luatti S, et al. Additional chromosomal abnormalities in Philadel-positive clone : Adverse prognostic influence on frontline imatinib therapy : A GIMEMA Working Party on CML analysis. Blood 2012 ; 120 : 761-7.
 
12) Hochhaus A, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020 ; 34 : 966-84.
PubMed
13) Millot F, et al. Additional cytogenetic abnormalities and variant t (9 ; 22) at the diagnosis of childhood chronic myeloid leukemia : The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents. Cancer 2017 ; 123 : 3609-16.
PubMed
14) Schmidt M, et al. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia 2014 ; 28 : 2292-9.
PubMed
15) Ernst T, et al. Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia. Leukemia 2018 ; 32 : 2046-9.
 
P.156 掲載の参考文献
1) Baccarane M, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia :2013. Blood 2013 ; 122 : 872-84.
 
2) Hochhaus A, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020 ; 34 : 966-84.
PubMed
3) NCCN. NCCN Clinical Practice Guideline in Oncology : Chronic Myeloid Leukemia, Version 1. 2019. National Comprehensive Cancer Network ; 2018.
 
4) 日本小児血液・がん学会 (編). 小児白血病・リンパ腫診療ガイドライン 2016年版. 東京 : 金原出版 ; 2016.
 
5) O'Brien SG, et al. Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. N Eng J Med 2003 ; 348 : 994-1004.
 
6) Druker NJ, et al. Five-Year Follow-up of Patients Receiving lmatinib for Chronic Myeloid Leukemia. N Engl J Med 2006 ; 355 : 2408-17.
 
7) Cortes JE, et al. Final 5-Year Study of DASISION : The Dasatinib veersus Imaitnib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial. J Clin Oncol 2016 ; 34 : 2333-40.
 
8) Hochhaus A, et al. Long-tern benefits and risks of fontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase : 5-year update of the randomized ENESTnd trial. Leukemia 2016 ; 30 : 1044-54.
 
9) Hijiya N, et al. How I treat chronic myeloid leukemia in children and adolescents. Blood 2019 ; 133 : 2374-84.
 
10) Hijiya N, et al. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach : Blood 2016 ; 127 : 392-9.
PubMed
11) Kurosawa H, et al. Leukostasis in Children and Adolescents with Chronic Myeloid Leukemia : Japanese Pediatric Leukemia/Lymphoma Study Group. Pediatr Blood Cancer 2016 ; 63 : 406-11.
 
12) Millot F, et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase : results of the French national phase IV trial. J Clin Oncol 2011 ; 29 : 2827-32.
PubMed
13) Gore L, et al. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase : Results From a Phase II Trial. J Clin Oncol 2018 ; 36 : 1330-8. -positive chronic myeloid leukemia. Blood 2019 ; 134 : 2036-45.
 
15) Talpez M, et al. Imatinib induced durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia : results of a phase 2 study. Blood 2002 ; 99 : 1928-37.
PubMed
16) Shima H, et al. Distinct Impact of Imatinib on Growth at Prepubertal and Pubertal Ages of Children with Chronic Myeloid Leukemia. J Pediatr 2011 ; 159 : 676-81.
PubMed
17) Etienne G, et al. Long-term follow-up of the French Stop Imatinib (STIm1) Study in Patients with Chronic Myeloid Leukemia. J Clin Oncol 2017 ; 35 : 298-305.
PubMed
18) Shima H, et al. Discontinuation of Tyrosine Kinase Inhibitor in Children with Chronic Myeloid Leukemia (JPSLG STKI-14 study). Blood 2019 : 134 (Supplement 1) : 25.
 
P.161 掲載の参考文献
1) Millot F, et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase : results of the French national phase IV trial. J Clin Oncol 2011 ; 29 : 2827-32.
PubMed
2) Suttorp M, et al. Treatment of pediatric chronic myeloid leukemia in the year 2010 : use of tyrosine kinasse inhibitors and stem-cell transplantation. Hematology Am Soc Hematol Educ Program 2010 ; 2010 : 368-76.
 
3) Tanizawa A. Optimal management for pediatric chronic myeloid leukemia. Pediatr Int 2016 ; 58 : 171-9.
PubMed
4) Hughes TP, et al ; International Randomised Study of Interferon versus ST1571 (IRIS) Study Group. Frequency of interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003 ; 349 : 1423-32.
 
5) Shima H, et al. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr 2011 ; 159 : 676-81.
PubMed
6) Andolina JR, et al. Practice Patterns of Physician Treatment for Pediatric Chronic Myelogenous Leukemia. Biol Blood Marrow Transplant 2019 ; 25 : 321-7.
PubMed
7) de la Fuente J, et al. Managing children with chronic myeloid leukemia (CML) : recommendations for the management of CML in children and young people up to the age of 18 years. Br J Haematol 2014 ; 167 : 33-47.
 
8) Athale U, et al. Management of chronic myeloid leukemia in children and adolescents : Recommendations from the Children's Oncology Group CML Working Group. Pediatr Blood Cancer 2019 ; 66 : e27827.
 
9) Hochhaus A, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020 ; 34 : 966-84.
PubMed
10) Mahon FX, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years : the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010 ; 11 : 1029-35.
PubMed
11) Saussele S, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI) : a prespecified interim analysis of a prospective, multicentre, non-Randomised, trial. Lancet Oncol 2018 ; 19 : 747-57.
 
12) Moser O, et al. Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia. Pediatr Blood Cancer 2014 ; 61 : 2080-2.
PubMed
13) Millot F, et al. Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase. Pediatric Blood Cancer 2015 ; 61 : 355-7.
 
14) de Bruijn CMA, et al. Discontinuation of imatinib in children with chronic myeloid leukaemia in sustained deep molecular remission : results of the STOP IMAPED study. Br J Haematiol 2019 ; 185 : 718-24.
PubMed
15) Shima H, et al. Discontinuation of Tyrosine Kinase Inhibitor in Children with Chronic Myeloid Leukemia (JPSLG STKI-14 study). Blood 2019 : 134 (Supplement 1) : 25.
 
16) Millot F, et al. Favourable outcome or de novo advanced phases of childhood chronic myeloid leukaemia. Eur J Cancer 2019 ; 115 : 17-23.
 
17) Meyran D, et al. Lymphoblastic predominance of blastic phase in children with chronic myeloid leukaemia treated with imatinib : A report from the I-CML-Ped Study. Eur J Cancer 2020 ; 137 : 224-34.
PubMed

6章 骨髄異形成症候群・骨髄増殖性疾患

P.167 掲載の参考文献
1) Hahn CN, et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet 2011 ; 43 : 1012-7.
PubMed
2) Ostergaard P, et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet 2011 ; 43 : 929-31.
PubMed
3) Dickinson RE, et al. Exome sequencing identifies GATA-2 mutation as the cause or dendritic cell, monocyte, B and NK lymphoid deficiency. Blood 2011 ; 118 : 2656-8.
PubMed
4) Hsu AP, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 2011 ; 118 : 2653-5.
PubMed
5) Micol JB, Abdel-Wahab O. Collaborating constitutive and somatic genetic events in myeloid malignancies : ASXL1 mutations in patients with germline GATA2 mutations. Haematologica 2014 ; 99 : 201-3.
PubMed
6) Wang X, et al. GATA2 and secondary mutations in familial myelodysplastic syndromes and pediatric myeloid malignancies. Haematologica 2015 ; 100 : e398-401.
PubMed
7) Song WJ, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999 ; 23 : 166-75.
PubMed
8) Owen CJ, et al. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood 2008 ; 112 : 4639-45.
PubMed
9) Yoshimi A, et al. Recurrent CDC25C mutations drive malignant transformation in FPD/AML. Nat Commun 2014 ; 5 : 4770.
PubMed
10) Smith ML, et al. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med 2004 ; 351 : 2403-7.
PubMed
11) Pippucci T, et al. Mutations in the 5'UTR of ANKRD26, the ankirin repeat domain 26 gene, cause an autosomal-dominant form of inherited thrombocytopenia, THC2. Am J Hum Genet 2011 ; 88 : 115-20.
PubMed
12) Noris P, et al. ANKRD26-related thrombocytopenia and myeloid malignancies. Blood 2013 ; 122 : 1987-9.
PubMed
13) Narumi S, et al. SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7. Nat Genet 2016 ; 48 : 792-7.
 
14) Schwartz JR, et al. Germline SAMD9 mutation in siblings with monosomy 7 and myelodysplastic syndrome. Leukemia 2017 ; 31 : 1827-30.
PubMed
15) Schwartz JR, et al. The genomic landscape of pediatric myelodysplastic syndromes. Nat Commun 2017 ; 8 : 1557.
PubMed
16) Alter BP, et al. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol 2010 ; 150 : 179-88.
PubMed
17) Alter BP, et al. Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up. Haematologica 2018 ; 103 : 30-9.
PubMed
18) Lindsley RC, et al. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med 2017 ; 376 : 536-47.
PubMed
19) Cada M, et al. The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromes. Haematologica 2015 ; 100 : 633-42.
PubMed
P.177 掲載の参考文献
1) 長谷川大輔. 小児骨髄異形成症候群とその鑑別診断. 日小児血がん会誌 2019 ; 56 : 1-7.
Medical*Online
2) Locatelli F, Strahm B. How I treat myelodysplastic syndromes of childhood. Blood 2018 ; 131 : 1406-14.
 
3) Arber DA, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016 ; 127 : 2391-405.
 
4) Hasle H, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003 ; 17 : 277-82.
 
5) Hasegawa D. The current perspective of lowgrade myelodysplastic syndrome in children. Int J Hematol 2016 ; 103 : 360-4.
PubMed
6) Kardos G, et al. Refractory anemia in childhood : a retrospective analysis of 67 patients with particular reference to monosomy 7. Blood 2003 ; 102 : 1997-2003.
PubMed
7) Hasegawa D, et al. Clinical characteristics and treatment outcome in 65 cases with refractory cytopenia of childhood defined according to the WHO 2008 classification. Br J Haematol 2014 ; 166 : 758-66.
 
8) Strahm B, et al. Hematopoietic stem cell transplantation for advanced MDS in children : results of the EWOG-MDS98 study. Leukemia 2011 ; 25 : 455-62.
PubMed
9) Kikuchi A, et al. Outcome of children with refractory anaemia with excess of blast (RAEB) and RAEB in transformation (RAEB-T) in the Japanese MDS99 study. Br J Haematol 2012 ; 158 : 657-61.
PubMed
10) Niemeyer CM, Baumann I. Classification of childhood aplastic anemia and myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program 2011 ; 2011 : 84-9.
PubMed
11) Bluteau O, et al. A landscape of germ line mutations in a cohort of inherited bone marrow failure patients. Blood 2018 ; 131 : 717-32.
 
12) Hama A, et al. Comparison of long-term outcomes between children with aplastic anemia and refractor cytopenia of childhood who reccived immunosuppressive therapy with antithymocyte globulin and cyclosporine. Haematologica 2015 ; 100 : 1426-33.
 
13) Forester CM, et al. Pediatric aplastic anemia and refractory cytopenia : A retrospective analysis assessing outcomes and histomorphologic predictors. Am J Hematol 2015 ; 90 : 320-6.
PubMed
14) Yosimi A, et al. Comparison of horse and rabbit antithymocyte globulin in immunosuppressive therapy for refractory cytopenia of childhood. Haematologica 2014 ; 99 : 656-63.
 
15) Stary J, et al. Stem cell transplantation for aplastic anemia and myelodysplastic syndrome. Bone Marrow Transplant 2005 ; 35 (Suppl 1) : S13-6.
 
16) Strahm B, et al. Reduced intensity conditioning in unrelated donor transplantation for refractory cytopenia in childhood. Bone Marrow Transplant 2007 ; 40 : 329-33.
PubMed
17) Yoshida N, et al. Conditioning regimen for allogeneic bone marrow transplantation in children with acquired bone marrow failure : fludarabine/melphalan vs. fludarabine/cyclophosphamide. Bone Marrow Transplant 2020 ; 55 : 1272-81.
PubMed
18) Waespe N, et al. Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation. Haematologica 2016 ; 101 : 1508-15.
PubMed
P.183 掲載の参考文献
1) 吉田奈央, ほか. 若年性骨髄単球性白血病75例の予後. 小児血液学会MDS委員会の前方視的検討. 臨床血液 2011 ; 52 ; 1853.
 
2) Niemeyer CM, et al. Juvenile myelomonocytic leukemia : who's the driver at the wheel? Blood 2019 ; 133 : 1060-70.
PubMed
3) Doisaki S, et al. Somaticmosaicism for oncogenic NRAS mutations in juvenile myelomonocytic leukemia. Blood 2012 ; 120 : 1485-8.
PubMed
4) Kato M, et al. Aggressive transformation of juvenile myelomonocytic leukemia associated with uniparental disomy. J Pediatr 2013 ; 162 : 1285-8.
PubMed
5) Takagi M, et al. Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation. Blood 2011 ; 117 : 2887-90.
PubMed
6) Tartaglia M, et al. Somatic mutation in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003 ; 34 : 148-50.
PubMed
7) Shannon KM, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 1994 ; 330 : 597-601.
PubMed
8) Niemeyer CM, et al. Germline CBL mutations cause developmental myelomonocytic leukemia. Nat Genet 2010 ; 42 : 794-800.
PubMed
9) Flex E, et al. Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis. Hum Mol Genet 2014 ; 23 : 4315-27.
PubMed
10) Sakaguchi H, et al. Exonne sequcncing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet 2013 ; 45 : 937-41.
PubMed
11) Stieglitz E, et al. The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet 2015 ; 47 : 1326-33.
PubMed
12) Caye A, et al. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. Nat Genet 2015 ; 47 : 1334-40.
PubMed
13) Murakami N, et al. Integrated molecular profiling of juvenile myelomonocytic leukemia. Blood 2018 ; 131 : 1576-86.
PubMed
14) Chao A, et al. Fusion driven JMML : a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing. Leukemia 2020 ; 34 : 662-6.
PubMed
15) Bresolin S, et al. Gene expression-based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia. J Clin Oncol 2010 ; 28 : 1919-27.
PubMed
16) Lipka DB, et al. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia. Nat Commun 2017 ; 8 : 2126.
PubMed
17) Stieglitz E, et al. Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. Nat Commun 2017 ; 8 : 2127.
PubMed
P.190 掲載の参考文献
1) Niemeyer CM, et al. Chronic myelomonocytic leukemia in childhood : a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood 1997 ; 89 : 3534-43.
 
2) Emanuel PD, et al. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 1991 ; 77 : 925-9.
PubMed
3) Arico M, et al. Juvenile myelomonocytic leukemia. Blood 1997 ; 90 : 479-88.
PubMed
4) Miyauchi J, et al. Mutations of the N-ras gene in juvenile chronic myelogenous leukemia. Blood 1994 ; 83 : 2248-54.
 
5) Shannon KM, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 1994 ; 330 : 597-601.
PubMed
6) Fukuda M, et al. Spontaneous remission of juvenile chronic myelomonocytic leukemia in an infant with Noonan syndrome. J Pediatr Hematol Oncol 1997 ; 19 : 177-9.
 
7) Tartaglia M, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003 ; 34 : 148-50.
PubMed
8) Niemeyer CM, et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet 2010 ; 42 : 794-800.
PubMed
9) Arber DA, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016 ; 127 : 2391-405.
 
10) Matsuda K, et al. Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Blood 2007 ; 109 : 5477-80.
PubMed
11) Yoshida N, et al. Correlationn of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia. Pediatr Res 2009 ; 65 : 334-40.
 
12) Sakaguchi H, et al. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet 2013 ; 45 : 937-41.
PubMed
13) Murakami N, et al. Ineegrated molecular profiling of juvenile myelomonocytic leukemia. Blood 2018 ; 131 : 1576-86.
PubMed
14) Locatelli F, Niemeyer CM. How I treat juvenile myelomonocytic leukemia. Blood 2015 ; 125 : 1083-90.
 
15) Locatelli F, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML) : results of the EWOG-MDS/EBMT trial. Blood 2005 ; 105 : 410-9.
 
16) Yoshida N, et al. Clinical outcomes after allogeneic hematopoietic stem cell transplantation in children with juvenile myelomonocytic leukemia : A report from the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2020 ; 26 : 902-10.
 
17) Locatelli F, et al. Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia : a EUROCORD, EBMT, EWOG-MDS, CIB-MTR study. Blood 2013 ; 122 : 2135-41.
 
18) Cseh A, et al. Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia : a retrospective analysis of the EWOG-MDS study group. Blood 2015 ; 125 : 2311-3.
 

7章 リンパ腫・リンパ増殖性疾患

P.202 掲載の参考文献
1) Swerdlow SH, et al (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed., Revised ed. Lyon : International Agency for Research on Cancer ; 2017.
 
2) Cairo MS, et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (>/=15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma : results of the FAB LMB 96 study. J Clin Oncol 2012 ; 30 : 387-93.
 
2) Swerdlow SH, et al (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon : IARC Press ; 2008.
 
3) Leticia QM. The 2016 updated WHO classification of lymphoid neoplasias. Hematological Oncology 2017 ; 35 : 37-45.
 
3) Tsurusawa M, et al. Improved treatment results of children with B-cell non-Hodgkin lymphoma : A report from the Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL03 study. Pediatr Blood Cancer 2014 ; 61 : 1215-21.
 
4) Swerdlow SH, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016 ; 127 : 2375-90.
PubMed
4) Minard-Colin V, et al. Riluximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. N Engl J Med 2020 ; 382 : 2207-19.
PubMed
5) Osumi T, et al. Relapsed/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy : A report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Pediat Blood Cancer 2016 ; 63 : 1794-9.
 
5) Burkhardt B, et al. Poor outcome for children and adolescents with progressive disease or relapse of lynmphoblastic lymphoma : a report from the Berlin-Frankfurt-Muenster group. J Clin Oncol 2009 ; 27 : 3363-9.
 
6) Reiter A, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% eventfree survival for children with T-cell lymphoblastic lymphoma : a BFM group report. Blood 2000 ; 95 : 416-21.
 
6) He L, et al. A microRNA polycistron as apotential huma oncogene. Nature 2005 ; 435 : 828-33.
 
7) Hammond SM. MicroRNAs as oncogenes. Curr Opin Genet Dev 2006 ; 16 : 4-9.
PubMed
7) Gurkhardt B, et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III of IV lymphoblastic lymphoma. J Clin Oncol 2006 ; 24 : 491-9.
 
8) Landmann E, et al. Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma. Haematologica 2017 : 102 : 2086-96.
PubMed
8) Love C, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012 ; 44 : 1321-5.
PubMed
9) Richter J, et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome exome and transcriptome sequencing. Nat Genet 2012 ; 44 : 1316-20.
PubMed
9) Sunami S, et al. Prognostic Impact of Intensified Maintenance Therapy on Children With Advanced Lymphoblastic Lymphoma : A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group ALB-NHL03 Study. Pediat Bliid Cancer 2016 ; 63 : 451-7.
 
10) Schmitz R, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functiona genomics. Nature 2012 ; 490 : 116-20.
 
10) Seidemann K, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma : a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 2001 ; 97 : 3699-706.
PubMed
11) Laver JH, et al. Advanced-stage large-cell lymphoma in children and adolescents : results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen : a Pediatric Oncology Group phase III trial. J Clin Oncol 2005 ; 23 : 541-7.
PubMed
11) Wagener R, et al. The PCBP1 gene encoding poly (rC) binding protein I is recurrently mutated in Burkitt lymphoma. Genes Chromosomes Cancer 2015 ; 54 : 555-64.
 
12) Brug) Brugieres L, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma : results of a randomized trial of the EICNHL Group. J Clin Oncol 2009 ; 27 : 897-903.
 
12) Salaverria I, et al. A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood 2014 ; 123 : 1187-98.
PubMed
13) Brugieres L, et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma : a report from the French Society of Pediatric Oncology. J Clin Oncol 2009 ; 27 : 5056-61.
PubMed
13) Hans CP, et al. Confirmation or the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004 ; 103 : 275-82.
 
14) Pasqualucci L, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nature Genet 2011 ; 43 : 830-7.
PubMed
14) Mosse YP,
 
15) Pasqualucci L, Dalla-Favcra R. The genetic landscape of diffuse large B-cell lymphoma. Semin Hematol 2015 ; 52 : 67-76.
 
15) Fukano R, et al. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma : An open-label phase II trial. Cancer Sci 2020 ; 111 : 4540-7.
PubMed
16) Copie-Bergman C, et al. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy : a GELA/LYSA study. Blood 2015 ; 126 : 2466-74.
PubMed
17) Liu Q, et al. Follicular lymphomas in children and young adult : a comparison of the pediatric variant with usual follicular lymphoma. Am J Phathol 2013 ; 37 : 333-43.
 
18) Salaverria I, et al. Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood 2o11 ; 118 : 139-47.
 
19) Martin GI, et al. Recurrent loss of heterozygosity in 1p36 associated with TNFRSF14 mutations in IRF4 translocation negative pediatric follicular lymphomas. Haematologica 2013 ; 98 : 1237-41.
 
20) Abner L, et al. Pediatric-type nodal follicular lymphoma : a biologically distinct lymphoma with frequent MAPK pathway mutations. Blood 2016 ; 128 : 1093-100.
 
21) Reiter A, et al. Non-Hodgkin's lymphomas of childhood and adolescence : results of a treatment statified for biologic subtypes and stage-a report of the Berlin-Frankfurt-Munster Group. J Clin Oncol 1995 ; 13 : 359-72.
 
22) Burkhardt B, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 2005 ; 131 : 39-49.
PubMed
23) Maitra A, et al. Precursor B-cell lymphoblastic lymphoma. A study of nine cases lacking blood and bone marrow involvement and review of literature. Am J Clin Pathol 2001 ; 115 : 868-75.
PubMed
24) Schraders M, et al. High-resolution genemic profiling of pediatric lymphoblastic lymphomas reveals subtle differences with pediatric acute lymphoblastic leukemias in the B-lineage. Cancer Genet Cytogenet 2009 ; 191 : 27-33.
 
25) Bonn BR, et al. Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence. Blood 2013 ; 121 : 3153-60.
 
26) Callens C, et al. Clinical impact of NOTCH1 and/or FBXW7 mutations. FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma. J Clin Oncol 2012 ; 30 : 1966-73.
PubMed
27) Balbach ST, et al. Proposal of a genetic classifyer for risk group stratifyication in pediatric T-cell lymphoblastic leukemia. Leukemia 2016 ; 30 : 970-3.
 
28) Yang YL, et al. Absence of biallelic TCYγ deletion predicts induction failure and poorer outcomes in childhood T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer 2012 ; 58 : 846-51.
 
29) Krieger D, et al. Frequency and clinical relevance of DNA microsatellite alterations of the CDKN2A/B, ATM and p53 gene loci : a comparison between pediatric precursor T-cell lymphoblastic lymphoma and T-cell lymphoblastic leukemia. Haematologica 2010 ; 95 : 158-62.
 
30) Bonn BR, et al. Whole exome sequencing hints at a unique mutational profile of paediatric T-cell lymphoblastic lymphoma. Br J Haematol 2015 ; 168 : 308-13.
 
31) Park MJ, et al. FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol 2009 ; 145 : 198-206.
 
32) Hayashi Y, et al. Abnormalities of the long arm of chromosome 6 in childhood acute lymphoblastic leukemia. Blood 1990 ; 76 : 1626-30.
 
33) Damm Welk C, et al. Distribution of NPM1-ALK and X-ALK fusion transcripts in paediatric anaplastic large cell lymphoma : a molecular-histological correlation. Br J Haematol 2009 ; 146 : 305-9.
 
P.209 掲載の参考文献
1) Woessmann W, et al : Group BFM. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms : a report of the BFM Group Study NHL-BFM95. Blood 2005 ; 105 : 948-58.
 
P.215 掲載の参考文献
1) Steidl C, et al. Molecular pathogenesis of Hodgkin's lymphoma : increasing evidence of the importance of the microenvironment. J Clin Oncol 2011 ; 29 : 1812-26.
PubMed
2) Gravelle P, et al. Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma : a summary of immunohistochemical studies. Oncotarget 2017 ; 8 : 44960-75.
PubMed
3) Clerici M, et al. Multiple defects of T helper cell function in newly diagnosed patients with Hodgkin's disease. Eur J Cancer 1994 ; 30A : 1464-70.
PubMed
4) Rudant J, et al. Childhood Hodgkin's lymphoma, non-Hodgkin's lymphoma and factors related to the immune system : the Escale Study (SFCE). Int J Cancer 2011 ; 129 : 2236-47.
 
5) Kharazmi E, et al. Risk of familial classical Hodgkin lymphoma by relationship, histology, age, and sex : a joint study from five Nordic countries. Blood 2015 ; 126 : 1990-5.
PubMed
6) Anghelescu DL, et al. Clinical and diagnostic imaging findings predict anesthetic complications in children presenting with malignant mediastinal masses. Paediatr Anaesth 2007 ; 17 : 1090-8.
PubMed
7) Cheson BD, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014 ; 32 : 3059-68.
PubMed
8) Lister TA, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease : Cotswolds meeting. J Clin Oncol 1989 ; 7 : 1630-6.
PubMed
9) Mauz-Korholz C, et al. Pediatric Hodgkin Lymphoma. J Clin Oncol 2015 ; 33 : 2975-85.
PubMed
10) Koga Y, et al. [Retrospective analysis of 157 patients with pediatric Hodgkin lymphoma in Japan : investigation by four pediatric cancer study groups] Rinsho Ketsueki 2012 ; 53 : 443-9.
PubMed
11) Koga Y, et al. The Effect of Interim FDG-PET-guided Response-Adapted Therapy in Pediatric Patients with Hodgkin's Lymphoma (HL-14) : Protocol for a Phase II Study. Acta Med Okayama 2018 ; 72 : 437-40.
PubMed
12) Lopci E, et al. FDG PET in response evaluation of bulky masses in paediatric Hodgkin's lymphoma (HL) patients enrolled in the Italian AIEOP-LH2004 trial. Eur J Nucl Med Mol Imaging 2019 ; 46 : 97-106.
PubMed
13) Koga Y, et al. Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma. Int J Hematol 2020 ; 111 : 711-8.
 
14) Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma : 3-year update of the ECHELON-1 study. Blood 2020 ; 135 : 735-42.
PubMed
15) Davis KL, et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412) : a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol 2020 ; 21 : 541-50.
 
16) Keller FG, et al. Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma : A report from the Children's Oncology Group. Cancer 2018 ; 124 : 3210-9.
 
17) Oba U, et al. Donor lymphocyte infusion is an effective therapy for relapsed Hodgkin lymphoma after reduced-intensity allogeneic hematopoietic stem cell transplantation. Int J Hematol 2014 ; 100 : 511-3.
PubMed
18) Schaapveld M, et al. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. N Engl J Med 2015 ; 373 : 2499-511.
PubMed
P.225 掲載の参考文献
1) Bousfiha A, et al. The 2017 IUIS Phenotypic Classification for Primary Immunodeficiencies. J Clin Immunol 2018 ; 38 : 129-43.
PubMed
2) Seif AE, et al. Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome : a multi-institutional study. Blood 2010 ; 115 : 2142-5.
PubMed
3) Takagi M, et al. Genetic heterogeneity of uncharacterized childhood autoimmune diseases with lymphoproliferation. Pediatr Blood Cancer 2018 ; 65.
PubMed
4) Hadjadj J, et al ; members of the French Reference Center for Pediatric Autoimmune Cytopenia (CEREVANCE). Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes. Blood 2019 ; 134 : 9-21.
PubMed
5) Sneller MC, et al. A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. J Clin Invest 1992 ; 90 : 334-41.
 
6) Fisher GH, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995 ; 81 : 935-46.
 
7) Wu J, et al. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996 ; 98 : 1107-13.
 
8) Rao VK, Oliveira JB. How I treat autoimmune lymphoproliferative syndrome. Blood 2011 ; 118 : 5741-51.
 
9) Magerus-Chatinet A, et al. Autoimmune lymphoproliferative syndrome caused by a homozygous null FAS ligand (FASLG)mutation. J Allergy Clin Immunol 2013 ; 131 : 486-90.
PubMed
10) Straus SE, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 2001 ; 98 : 194-200.
PubMed
11) Rieux-Laucat F, et al. The Autoimmune Lymphoproliferative Syndrome with Defective FAS or FAS-Ligand Functions. J Clin Immunol 2018 ; 38 : 558-68.
 
12) Chun HJ, et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 2002 ; 419 : 395-9.
PubMed
13) Takagi M, et al. Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation. Blood 2011 ; 117 : 2887-90.
PubMed
14) Niemela JE, et al. Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. Blood 2011 ; 117 : 2883-6.
PubMed
P.232 掲載の参考文献
1) Schusteer V, Latour S. X-linked lymphoproliferative diseases. In : Ochs DH, et al (eds). Primary Immunodeficiency Diseases. New York : Oxford University Press ; 2014. p. 557-79.
 
2) Panchal N, et al. X-Linked Lymphoproliferative Disease type 1 : A Clinical and Molecular Perspective. Front Immunol 2018 ; 9 : 666.
PubMed
3) Filipovich AH, et al. X-linked lymphoproliferative syndromes : brothers or distant cousins? Blood 2010 ; 116 : 3398-408.
 
4) Aguilar C, Latour S. X-linked inhibitor or apoptosis protein deficiency : more than an X-linked lymphoproliferative syndrome. J Clin Immunol 2015 ; 35 : 331-8.
 
5) Ammann S, et al. A new functional assay for the diagnosis of X-linked inhibitor of apoptosis (XIAP) deficiency. Clin Exp Immunol 2014 ; 176 : 394-400.
PubMed
6) Wada T, et al. Sustained elevation of serum interleukin-18 and its association with hemophagocytic lymphohistiocytosis in XIAP deficiency. Cytokine 2014 ; 65 : 74-8.
PubMed
7) Pachlopnik Schmid J, et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood 2011 ; 117 : 1522-9.
PubMed
8) Aguilar C, et al. Characterization of Crohn disease in X-linked inhibitor of apoptosis-deficient male patients and female symptomatic carriers. J Allergy Clin Immunol 2014 ; 134 : 1131-41.e9.
 
9) Yang X, et al. A female patient with incomplete hemophagocytic lymphohistiocytosis caused by aheterozygous XIAP mutation associated with non-random X-chromosome inactivation skewed towards the wild-type XIAP allele. J Clin Immunol 2015 ; 35 : 244-8.
 
10) Yang X, et al. SAP and XIAP deficiency in hemophagocytic lymphohistiocytosis. Pediatr Int 2012 ; 54 : 447-54.
PubMed
11) Locatelli F, et al. Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. N Engl J Med 2020 ; 382 : 1811-22.
PubMed
12) Booth C, et al. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency : a multicenter study on the manifestations, management and outcome of the disease. Blood 2011 ; 117 : 53-62.
PubMed
13) Marsh RA, et al. Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1. Biol Blood Marrow Transplant 2014 ; 20 : 1641-5.
PubMed
14) Allen CE, et al. Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. Blood 2018 ; 132 : 1438-51.
PubMed
15) Marsh RA, et al. Allogeneic hematopoietic cell transplantation for XIAP deficiency : an international survey reveals poor outcomes. Blood 2013 ; 121 : 877-83.
PubMed
16) Ono S, et al. Hematopoietic Stem Cell Transplantation for XIAP Deficiency in Japan. J Clin Immunol 2017 ; 37 : 85-91.
PubMed
17) Rivat C, et al. SAP gene transfer restores cellular and humoral immune function in a murine model of X-linked lymphoproliferative disease. Blood 2013 ; 121 : 1073-6.
 
18) Panchal N, et al. Transfer of gene-corrected T cells corrects humoral and cytotoxic defects in patients with X-linked lymphoproliferative disease. J Allergy Clin Immunol 2018 ; 142 : 235-245.e6.
 
P.241 掲載の参考文献
1) Ghosh S, et al. Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency. Blood 2020 ; 136 : 2638-55.
PubMed
2) Izawa K, et al. Inherited CD70 deficiency in humans reveals a critical role for the CD70-CD27 pathway in immunity to Epstein-Barr virus infection. J Exp Med 2017 ; 214 : 73-89.
PubMed
3) Abolhassani H, et al. Combined immunodeficiency and Epstein-Barr virus-induced B cell malignancy in humans with inherited CD70 deficiency. J Exp Med 2017 ; 214 : 91-106.
PubMed
4) Somekh I, et al. CD137 deficiency causes immune dysregulation with predisposition to lymphomagenesis. Blood 2019 ; 134 : 1510-6.
PubMed
5) Rodriguez R, et al. Concomitant PIK3CD and TNFRSF9 deficiencies cause chronic active Epstein-Barr virus infection of T cells. J Exp Med 2019 ; 216 : 2800-18.
PubMed
6) Alosaimi MF, et al. Immunodeficiency and EBV-induced lymphoproliferation caused by 4-1BB deficiency. J Allergy Clin Immunol 2019 ; 144 : 574-583.e5.
 
7) Tangye SG, Latour S. Primary immunodeficiencies reveal the molecular requirements for effective host defense against EBV infection. Blood 2020 ; 135 : 644-55.
PubMed
8) Martin E, et al. Impaired lymphocyte function and differentiation in CTPS1-deficient patients result from a hypomorphic homozygous mutation. JCI Insight 2020 ; 5 : e133880.
PubMed
9) Ravell JC, et al. An Update on XMEN Disease. J Clin Immunol 2020 ; 40 : 671-81.
 
10) 日本小児感染症学会 (監). 慢性活動性EBウイルス感染症とその類縁疾患の診療ガイドライン 2016. 東京 : 診断と治療 ; 2016.
 
11) Fournier B, et al. Rapid identification and characterization of infected cells in blood during chronic active Epstein-Barr virus infection. J Exp Med 2020 ; 217 : e20192262.
PubMed
12) Collins PJ, et al. Characterising EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells. Blood 2021 ; 137 : 203-15.
PubMed
13) Okuno Y, et al. Defective Epstein-Barr virus in chronic active infection and haematological malignancy. Nat Microbiol 2019 ; 4 : 404-13.
PubMed
14) 荒井文子. 慢性活動性Epstein-Barr virus 感染症炎症と腫瘍, 2つの顔をもつ疾患. 聖マリアンナ医科大学雑誌 2019 ; 47 : 91-4.
 
15) Sawada A, et al. How we treat chronic active Epstein-Barr virus infection. Int J Hematol 2017 ; 105 : 406-18.
PubMed
16) Kawa K, et al. Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection. Bone Marrow Transplant 2011 ; 46 : 77-83.
PubMed
17) Kimura H, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts : prospective analysis of 108 cases. Blood 2011 ; 119 : 673-86.
PubMed
18) Yonese I, et al. Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification. Blood Adv 2020 ; 4 : 2918-26.
PubMed
19) Sawada A, et al. Umbilical Cord Blood as an Alternative Source of Reduced-Intensity Hematopoietic Stem Cell Transplantation for Chronic Epstein-Barr Virus-Associated T or Natural Killer Cell Lymphoproliferative Diseases. Biol Blood Marrow Transplant 2014 ; 20 : 214-21.
PubMed
20) Mayumi A, et al. Impact of melphalan dose during reduced-intensity conditioning on engraftment of cord blood transplantation for chronic Epstein-Barr virus-associated T or NK cell lymphoproliferative diseases. Pediatr Blood Cancer 2020 ; 67 : e28536.
PubMed
21) Miyake T, et al. Survival rates and prognostic factors of Epstein-Barr virus-associated hydroa vacciniforme and hypersensitivity to mosquito bites. Br J Dermatol 2015 ; 172 : 56-63.
PubMed
22) Tokura Y, et al. Hypersensitivity to mosquito bites as the primary clinical manifestation of ajuvenile type of Epstein-Barr virus-associated natural killer cell leukemia/lymphoma. J Am Acad Dermatol 2001 ; 45 : 569-78.
 
23) Toga A, et al. Clinical Significance of Cloned Expansion and CD5 Down-Regulation in Epstein-Barr Virus (EBV) -Infected CD8+ T Lymphocytes in EBV-Associated Hemophagocytic Lymphohistiocytosis. J Infect Dis 2010 ; 201 : 1923-32.
PubMed
24) 日本小児医血液・がん学会 組織球症委員会 (監). 小児HLH診療ガイドライン 2020 Vr1.0. https://www.jspho.org/pdf/journal/hlh/hlh2020_v1.pdf
 

8章 組織球症

P.251 掲載の参考文献
1) Durham BH. Molecular characterization of the histiocytoses : Neoplasia of dendritic cells and macrophages. Semin Cell Dev Biol 2019 ; 86 : 62-76.
PubMed
2) Swerdlow SH, et al (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed, Revised ed. Lyon : International Agency for Research on Cancer ; 2017.
 
3) Badalian-Very G, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010 ; 116 : 1919-23.
PubMed
4) Haroche J, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012 ; 120 : 2700-3.
 
5) Durham BH, et al. Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nat Med 2019 ; 25 : 1839-42.
PubMed
6) Papo M, et al. Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease) : from Oncogenic Mutations to Inflammatory Disorders. Curr Oncol Rep 2019 ; 21 : 62.
PubMed
7) Hayase T, et al. Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan. Int J Hematol 2020 ; 112 : 560-7.
PubMed
8) Picarsic J, et al. BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG) : a revised diagnostic algorithm to include pediatric Erdheim-Chester disease. Acta Neuropathol Commun 2019 ; 7 : 168.
PubMed
9) Xu J, et al. Systemic Juvenile Xanthogranuloma has a Higher Frequency of ALK Translocations than BRAFV600E Mutations. J Am Acad Dermatol 2020 ; S0190-9622 (20) 32445-2.
 
10) Allen CE, et al. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol 2010 ; 184 : 4557-67.
PubMed
11) Berres ML, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med 2014 ; 211 : 669-83.
PubMed
12) Milne P, et al. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood 2017 ; 130 : 167-75.
PubMed
13) Durham BH, et al. Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. Blood 2017 ; 130 : 176-80.
PubMed
14) Allen CE, et al. Langerhans-cell histiocytosis. N Engl J Med 2018 ; 379 : 856-68.
PubMed
15) Hervier B, et al. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood 2014 ; 124 : 1119-26.
 
16) Mass E, et al. A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. Nature 2017 ; 549 : 389-93.
PubMed
17) Papo M, et al. High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. Blood 2017 ; 130 : 1007-13.
PubMed
18) Hogstad B, et al. RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med 2018 ; 215 : 319-36.
PubMed
P.258 掲載の参考文献
1) Allen CE, et al. Langerhans-Cell Histiocytosis. N Engl J Med 2018 ; 379 : 856-68.
PubMed
2) Haroche J, et al. Histiocytoses : emerging neoplasia behind inflammation. Lancet Oncol 2017 ; 18 : e113-25.
PubMed
3) Emile JF, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016 ; 127 : 2672-81.
PubMed
4) Badalian-Very G, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010 ; 116 : 1919-23.
PubMed
5) Heritier S, et al. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy. J Clin Oncol 2016 ; 34 : 3023-30.
PubMed
6) Minkov M, et al. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group. Klinische Padiatrie 2000 ; 212 : 139-44.
 
7) Gadner H, et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr 2001 ; 138 : 728-34.
PubMed
8) Gadner H, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood 2008 ; 111 : 2556-62.
PubMed
9) Gadner H, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.Blood 2013 ; 121 : 5006-14.
PubMed
10) Morimoto A, et al. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis : Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. Cancer 2006 ; 107 : 613-9.
 
11) Morimoto A, et al. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis : results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. Int J Hematol 2016 ; 104 : 99-109.
 
12) Morimoto A, et al. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis : Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. Cancer 2006 ; 107 : 613-9.
 
13) Donadieu J, et al. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis : results of an international phase 2 study. Blood 2015 ; 126 : 1415-23.
PubMed
14) Rosso DA, et al. Reduced doses of cladribine and cytarabine regimen was effective and well tolerated in patients with refractory-risk multisystem Langerhans cell histiocytosis. Br J Haematol 2016 ; 172 : 287-90.
PubMed
15) Kudo K, et al. Nationwide retrospective review of hematopoietic stem cell transplantation in children with refractory Langerhans cell histiocytosis. Int J Hematol 2020 ; 111 : 137-48.
PubMed
16) Donadieu J, et al. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children : An International Observational Study. J Clin Oncol 2019 ; 37 : 2857-65.
PubMed
17) Sakamoto K, et al ; Japan LCH Study Group. Central diabetes insipidus in pediatric patients with Langerhans cell histiocytosis : Results from the JLSG-96/02 studies. Pediatr Blood Cancer 2018 : e27454.
 
18) McClain KL, et al. CNS Langerhans cell histiocytosis : Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer 2018 ; 124 : 2607-20.
PubMed
19) Imashuku S, et al. Follow-up of pediatric patients treated by IVIG for Langerhans cell histiocytosis (LCH) -related neurodegenerative CNS disease. Int J Hematol 2015 ; 101 : 191-7.
PubMed
P.264 掲載の参考文献
1) Emile JF, et al. Revised classification of histiocytoses and neoplasms or the macrophage-dendritic cell lineages. Blood 2016 ; 127 : 2672-81.
 
2) Dehner LP. Juvenile xanthogranulomas in the first two decades or life : a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations. Am J Surg Pathol 2003 ; 27 : 579-93.
PubMed
3) Janssen D, Harms D. Juvenile xanthogranuloma in childhood and adolescence : a clinicopathologic study of 129 patients from the kiel pediatric tumor registry. Am J Surg Pathol 2005 ; 29 : 21-8.
PubMed
4) Durham BH. Molecular characterization of the histiocytoses: Neoplasia of dendritic cells and macrophages. Semin Cell Dev Biol 2019 ; 86 : 62-76.
PubMed
5) Durham BH, et al. Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nat Med 2019 ; 25 : 1839-42.
PubMed
6) Picarsic J, et al. BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG) : a revised diagnostic algorithm to include pediatric Erdheim-Chester disease. Acta Neuropathol Commun 2019 ; 7 : 168.
PubMed
7) Xu J, et al. Systemic Juvenile Xanthogranuloma has a Higher Frequency of ALK Translocations than BRAFV600E Mutations. J Am Acad Dermatol 2020 ; S0190-9622 (20) 32445-2.
 
8) Samara WA, et al. Juvenile Xanthogranuloma Involving the Eye and Ocular Adnexa. Ophthalmology 2015 ; 122 : 2130-8.
PubMed
9) Rajendra B, et al. Successful treatment of ccntral nervous system juvenile xanthogranulomatosis with cladribine. Pediatr Blood Cancer 2009 ; 52 : 413-5.
PubMed
10) Maeda M, et al. Long-term outcomes of children with extracutaneous juvenile xanthogranulomas in Japan. Pediatr Blood Cancer 2020 ; 67 : e28381.
PubMed
11) Stover DG, et al. Treatment of juvenile xanthogranuloma. Pediatr Blood Cancer 2008 ; 51 : 130-3.
PubMed
12) Maintz L, et al. Successful treatment of systemic juvenile xanthogranulomatosis with cytarabine and 2-chlorodeoxyadenosine : case report and review of the literature. Br J Dermatol 2017 ; 176 : 481-7.
PubMed
P.268 掲載の参考文献
1) Haroche J, et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF (V600E) -mutated Erdheim-Chester disease. J Clin Oncol 2015 ; 33 : 411-8.
PubMed
2) Pegoraro F, et al. Erdheim-Chester disease : a rapidly evolving disease model. Leukemia 2020 ; 34 : 2840-57.
PubMed
3) Haroche J, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 2013 ; 121 : 1495-500.
PubMed
4) 山田剛大ほか. 第77回東海総合画像医学研究会講演論文集, 診断に苦慮した組織球症の1例. 映像情報メディカル 2015 ; 6 : 620-1.
 
5) Estrada-Veras JI, et al. The clinical spectrum of Erdheim-Chester disease : an observational cohort study. Blood Adv 2017 ; 1 : 357-66.
PubMed
6) Haroche J, et al. Erdheim-Chester disease. Blood 2020 ; 135 : 1311-8.
PubMed
7) Goyal G, et al. Erdheim-Chester disease : consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood 2020 ; 135 : 1929-45.
PubMed
8) Hervier B, et al. Association of both Langerhans cell histiocylosis and Erdheim-Chester disease linked to the BRAF V600E Mutation. Blood 2014 ; 124 : 1119-26.
 
9) Picarsic J, et al. BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG) : a revised diagnostic algorithm to include pediatric Erdheim-Chester disease. Acta Neuropathol Commun 2019 ; 7 : 168.
PubMed
10) Papo M, et al. High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. Blood 2017 ; 130 : 1007-13.
PubMed
11) Papo M, et al. Erdheim-Chester Disease : a Concise Review. Curr Rheumatol Rep 2019 ; 21 : 66.
PubMed
12) Toya T, et al. Prognostic factors of Erdheim-Chester disease : a nationwide survey in Japan. Haematologica 2018 ; 103 : 1815-24.
PubMed
13) Emile JF, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016 ; 127 : 2672-81.
PubMed
14) Cohen Aubart F, et al. Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). Blood 2017 ; 130 : 1377-80.
PubMed

9章 小児造血器腫瘍の支持療法

P.277 掲載の参考文献
1) O'Connor D, et al. Infection-related mortaiity in children wilh acute lymphoblastic leukemia : an analysis of infectious dcaths on UKALL2003. Blood 2014 ; 124 : 1056-61.
 
2) 日本造血細胞移植学会ガイドライン委員会. 造血細胞移植ガイドライン 造血細胞移植後の感染管理 (第4版). 日本造血細胞移植学会 ; 2017.
 
3) Whittington AM, et al. Bacterial contamination of stethoscopes on the intensive care unit. Anaesthesia 2009 ; 64 : 620-4.
PubMed
4) 日本環境感染学会ワクチン委員会 (編). 医療関係者のためのワクチンガイドライン 第3版. 日本環境感染学会 ; 2020.
 
5) 日本小児血液・がん学会 (編). 小児白血病・リンパ腫ガイドライン 2016年版. 東京 : 金原出版 ; 2016. p. 121-152.
 
6) Yeh TC, et al. Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis. Cancer 2014 ; 120 : 1255-62.
PubMed
7) 日本感染症学会, 日本化学療法学会JAID/JSC感染症治療ガイド・ガイドライン作成委員会敗血症ワーキンググループ. JAID/JSC感染症治療ガイドライン 2017 敗血症およびカテーテル関連血流感染症. 日本化学療法学会雑誌 2014 ; 66 : 84-117.
 
8) 日本小児科学会. 日本におけるパリビズマブの使用に関するコンセンサスガイドライン. https://www.jpeds.or.jp/uploads/files/20190402palivizumabGL.pdf.
 
9) Ruggiero A, et al. Covid-19and children with cancer : are they at increased risk or infection? Pediatr Res 2020. doi : 10.1038/s41390-020-0919-1. Online ahead of print.
 
10) 日本造血細胞移植学会ガイドライン委員会 予防接種 (第3版) 部会. 造血細胞移植ガイドライン 予防接種 (第3版). 日本造血細胞移植学会 ; 2018.
 
11) Gilbert DN, et al (eds). The Sanford Guide To Antimicrobial Therapy 2020. Antimicrobial Therapy ; 2020.
 
P.284 掲載の参考文献
1) 厚生労働省医薬・生活衛生局血液対策課. 輸血療法の実施に関する指針 (令和2年3月一部改正). https://www.mhlw.go.jp/content/11127000/000619338.pdf
 
2) 厚生労働省医薬・生活衛生局. 血液製剤の使用指針 (平成31年3月一部改正). https://www.mhlw.go.jp/content/11127000/000493546.pdf
 
3) 日本輸血・細胞治療学会. 赤血球型検査 (赤血球系検査) ガイドライン (改訂2版). 2016. http://yuketsu.jstmct.or.jp/wp-content/uploads/2016/10/5bc721e299263f6d44e2215cbdffbfaf.pdf
 
4) Mitchell L, et al. Increased endogenous thrombin generationin children with acute lymphoblastic leukemia : risk of thrombotic complicationsin L-asparaginase induced antithrombin III deficiency. Blood 1994 ; 83 : 386-91.
 
5) Bercovitz RS, Josephson CD. Thrombocytopenia and bleeding in pediatric oncology patients. Hematology Am Soc Hematol Educ Program 2012 ; 2012 : 499-505.
PubMed
6) British Committee for standards in Haematology, Blood Transfusion TaskForce : Guidelines for the use of platelet transfusions. Br J Haematol 2003 ; 122 : 10-23.
 
7) 日本輸血・細胞治療学会 輸血副作用対応ガイド改定版作成タスクフォース委員会 (編). ポケット版 わかりやすいベッドサイドの輸血ガイド. 東京 : 日本輸血・細胞治療学会 ; 2015.
 
8) 日本赤十字社. 日本赤十字社輸血情報 1804-159 輸血用血液製剤の安全対策の導入効果と輸血によるHBV, HCV及びHIV感染のリスク. http://www.jrc.or.jp/mr/relate/info/pdf/yuketsuj_1804159c.pdf
 
9) Josephson CD, et al. Blood transfusion and breast milk transmission of cytomegalovirus in very low-birth-weight infants : a prospective cohort study. JAMA Pediatr 2014 ; 168 : 1054-62.
PubMed
10) 日本輸血・細胞治療学会 宗教的輸血拒否に関する合同委員会報告. 宗教的輸血拒否に関するガイドライン. 2008. http://yuketsu.jstmct.or.jp/wp-content/themes/jstmct/images/medical/file/guidelines/Ref13-1.pdf http://yuketsu.jstmct.or.jp/wp-content/themes/jstmct/images/medical/file/guidelines/Rer13-2.pdf
 
P.291 掲載の参考文献
1) Hui D, et al. Quality of end-of-life care in patients with hematologic malignancies : a retrospective cohort study. Cancer 2014 ; 120 : 1572-8.
PubMed
2) Sexauer A, et al. Patterns of hospice use in patients dying from hematologic malignancies. J Palliat Med 2014 ; 17 : 195-9.
PubMed
3) Kassam A, et al. Predictors of and trends in high-intensity end-of-lire care among children with cancer : A population-based study using health services data. J Clin Oncol 2017 ; 35 : 236-42.
 
4) Kurashima AY, et al. A palliative prognostic score for terminally ill children and adolescents with cancer. Pediatr Blood Cancer 2010 ; 55 : 1167-71.
PubMed
5) Wolfe J, et al. Symptom and distress in children with advanced cancerr : prospective patient-reported outcomes from the PediQUEST study. J Clin Oncol 2015 ; 33 : 1928-35.
 
6) Matsuishi Y, et al. Verifying the validity and reliability of the Japanese version of the Face, Legs, Activity, Cry, Consolability (FLACC) Behavioral Scale. PLos One 2018 ; 13 : e0194094.
PubMed
7) von Baeyer CL, et al. Systematic review of observational (behavioral) measures of pain for children and adolescents aged 3 to 18 years. Pain 2007 ; 127 : 140-50.
PubMed
8) Ceelie I, et al. Effect of intravenous paracetamol on postoperative morphine requirements in neonates and infants undergoing major noncardiac surgery : a randomized controlled trial. JAMA 2013 ; 309 : 149-54.
PubMed
9) Zernikow B, et al. Pediatric palliative care : use of opioids for the management of pain. Paediatr Drugs 2009 ; 11 : 129-51.
PubMed
10) Yotani N, et al. Differences between Pediatricians and Internists in Advance Care Planning for Adolescents with Cancer. J Pediatr 2017 ; 182 : 356-62.
 
11) Weeks JC, et al. Patients'expectations about effects of chemotherapy for advanced cancer. NEJM 2012 ; 367 : 1616-25.
PubMed
12) Sisk BA, et al. How parents of children with cancer learn about their children's prognosis. Pediatrics 2018 ; 141 : e20172241.
 
13) Paladino J, et al. Communication strategies for sharing prognostic information with patients. JAMA 2019 ; 322 : 1345-6.
PubMed
14) Kamihara J, et al. Parental hope for children with advanced cancer. Pediatrics 2015 ; 135 : 868-74.
PubMed

10章 小児造血器腫瘍の晩期合併症

P.297 掲載の参考文献
1) Oeffinger KC, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006 ; 355 : 1572-82.
PubMed
2) Meadows AT, et al. Second malignant neoplasms in children : An update from the late effects study group. J Clin Oncol 1985 ; 3 : 532-8.
 
3) Neglia JP, et al. Second malignant neoplasms in five years survivors of childhood cancer : childhood cancer survivors study. J Natl Cancer Inst 2001 ; 93 : 618-29.
PubMed
4) Meadows AT, et al. Second neoplasms in survivors of childhood cancer : findings from the Childhood Cancer Survivors Study cohort. J Clin Oncol 2009 ; 27 : 2356-62.
PubMed
5) Friedman DL, et al. Subsequent neoplasms in 5-year survivors of childhood cancer : Childhood Cancer Survivors Study. J Natl Cancer Inst 2010 ; 102 : 1083-95.
PubMed
6) Schmiegelow K, et al. Second Malignant Neoplasms After Treatment of Childhood Acute Lymphoblastic Leukemia. J Clin Oncol 2013 ; 31 : 2469-76.
PubMed
7) 石田也寸志. 小児白血病・リンパ腫の後期合併症と長期フォローアップ. 小児科診療 2010 ; 8 : 1413-20.
Medical*Online
8) Henderson TO, et al. Breast Cancer Risk in Childhood Cancer Survivors Without a History of Chest Radiotherapy : A Report From the Childhood Cancer Survivor Study. J Clin Oncol 2016 ; 34 : 910-8.
PubMed
9) 熱田由子, 石田也寸志. 二次がん. 日本造血細胞移植学会ガイドライン 第4巻 移植後長期フォローアップ, 名古屋 : 日本造血細胞移植学会 ; 2017. p.116-21.
 
10) Children's Oncology Group. Long-Term Follow-Up Guidelines. Version 5.0. 2018. p. 1-232. http://www.survivorshipguidelines.org/pdf/2018/COG_LTFU-Guidelines_v5.pdf
 
11) Clement SC, et al. Balancing the benefits and harms of thyroid cancer surveillance in survivors of Childhood, adolescent and young adult cancer : Recommendations from the international Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. Cancer Treat Rev 2018 ; 63 : 28-39.
 
12) Teepen JC, et al. Risk of subsequent gastrointestinal cancer among childhood cancer survivors : A systematic review. Cancer Treat Rev 2016 ; 43 : 92-103.
PubMed
P.303 掲載の参考文献
1) Brignardello E, et al. Endocrine health conditions in adult survivors of childhood cancer : The need for specialized adult-focused follow-up clinics. Eur J Endocrinol 2013 ; 168 : 465-72.
PubMed
2) Grois N, et al. Risk factors for diabetes insipidus in langerhans cell histiocytosis. Pediatr Blood Cancer 2006 ; 46 : 228-33.
PubMed
3) Barroso-Sousa R, et al. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens : A Systematic Review and Meta-analysis. JAMS Oncol 2018 ; 4 : 173-82.
 
4) Chemaitilly W, et al. Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy : A report from the St Jude Lifetime Cohort study. J Clin Oncol 2015 ; 33 : 492-500.
PubMed
5) Sklar C, et al. Abnormalities of the thyroid in survivors of Hodgkin's disease : Data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2000 ; 85 : 3227-32.
PubMed
6) Zhang FF, et al. Obesity in pediatric ALL survivors : A meta-analysis. Pediatrics 2014 ; 133 : e704-15.
PubMed
7) Friedman DN, et al. Cardiovascular risk factors in survivors of childhood hematopoietic cell transplantation treated with total body irradiation : A longitudinal analysis. Biol Blood Marrow Transplant 2017 ; 23 : 475-82.
PubMed
8) Hoffmeister PA, et al. Diabetes mellitus in long-term survivors of pediatric hematopoietic cell transplantation. J Pediatr Hematol Oncol 2004 ; 26 : 81-90.
PubMed
9) Gibson TM, et al. Blood Pressure Status in Adult Survivors of Childhood Cancer : A Report from the St. Jude Lifetime Cohort Study. Cancer Epidemiol Biomarkers Prev 2017 ; 26 : 1705-13.
PubMed
10) Hudson MM, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA 2013 ; 309 : 2371-81.
PubMed
11) 日本小児内分泌学会. 移行期医療支援ガイド. http://jspe.umin.jp/medical/transition.html
 
12) 日本小児内分泌学会CCS委員会. 小児がん経験者 (CCS) のための医師向けフォローアップガイド (ver 1.2). http://jspe.umin.jp/medical/files/guide161006.pdf
 
P.308 掲載の参考文献
1) Loren AW, et al. Fertility preservation for patients with cancer ; American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2013 ; 31 : 2500-10.
 
2) 日本癌治療学会 (編). 小児, 思春期・若年がん患者の妊孕性温存に関する診療ガイドライン 2017年版. 東京 : 金原出版 ; 2017.
 
3) Children's Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers Version 5.0. www.survivorshipguidelines.org/
 
4) Green DM, et al. The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure : a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 2014 ; 61 : 53-67.
PubMed
5) Chow E, et al. Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999 : a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol 2016 ; 17 : 567-76.
PubMed
6) Green DM, et al. Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer : a report from the St Jude Lifetime Cohort Study. Lancet Oncol 2014 ; 15 : 1215-23.
PubMed
7) Skinner R, et al. Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors : a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. Lancet Oncol 2017 ; 18 : e75-90.
 
8) Van Dorp, et al. Recommendations for Premature Ovarian Insufficiency Sureillance for Female Survivors of Childhood, Adolescent, and Young Adult Cancer : A Report From the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration With the PanCareSurFup Consortium. J Clin Oncol 2016 ; 34 : 3440-50.
 
9) Chemantilly W, et al. Premature Ovarian Insufficiency in Childhood Cancer Survivors : A Report From the St. Jude Lifetime Cohort. J Clin Endocrinol Metab 2017 ; 102 : 2242-50.
 
10) Levin JM, et al. Nonsurgical premature menopause and reproductive implications in survivors of childhood cancer : A report from the Childhood Cancer Survivor Study. Cancer 2018 ; 124 : 1044-52.
 
11) Brooke RJ, et al. A High-risk Haplotype for Premature Menopause in Childhood Cancer Survivors Exposed to Gonadotoxic Therapy. J Natl Cancer Inst 2018 ; 110 : 895-904.
PubMed
12) Green D, et al. Ovarian Failure and Reproductive Outcomes After Childhood Cancer Treatment : Results From the Childhood Cancer Survivor Study. J Clin Oncol 2009 ; 27 : 2374-81.
PubMed
13) Clark R, et al. Predicting acute ovarian failure in female survivors of childhood cancer : a cohort study in the Childhood Cancer Survivor Study (CCSS) and the St Jude Lifetime Cohort (SJLIFE). Lancet Oncol 2020 ; 21 : 436-45.
PubMed
14) Balduzzi A, et al. Fertility preservation issues in pediatric hematopoietic stem cell transplantation : practical approaches from the consensus of the Pediatric Diseases Working Party of the EBMT and the International BFM Study Group. Bone Marrow Transplant 2017 ; 52 : 1406-15.
 
15) Wallace WH, et al. Fertility preservation for girls and young women with cancer : population-based validation of criteria for ovarian tissue cryopreservation. Lancet Oncol 2014 ; 15 : 1129-36.
 
16) Poirot C, et al. Post-transplant outcome of ovarian tissue cryopreserved after chemotherapy in hematologic malignancies. Haematologica 2019 ; 104 : e360-3.
PubMed
P.314 掲載の参考文献
1) Suter TM, Ewer MS. Cancer drugs and the heart : importance and management. Eur Heart J 2013 ; 34 : 1102-11.
PubMed
2) Von Hoff DD, et al. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med 1977 ; 62 : 200-8.
PubMed
3) Ishida S, et al. The clinical features of fatal cyclophosphamide-induced cardiotoxicity in a conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Ann Hematol 2016 ; 95 : 1145-50.
 
4) Tan C, et al. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer 1967 ; 20 : 333-53.
PubMed
5) Tewey KM, et al. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984 ; 226 : 466-8.
PubMed
6) Rochette L, et al. Anthracyclines/trastuzumab : new aspects of cardiotoxicity and molecular mechanisms. Trends Pharmacol Sci 2015 ; 36 : 326-48.
PubMed
7) Swain Sm, et al. Congestive heart failure in patients treated with doxorubicin : a retrospective analysis of three trials. Cancer 2003 ; 97 : 2869-79.
PubMed
8) Zamorano JL, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines : The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016 ; 37 : 2768-801.
 
9) 前田美穂. 小児がん治療後の長期フォローアップガイドライン. 大阪 : 医薬ジャーナル ; 2013.
 
10) Armenian SH, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer : a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2015 ; 16 : e123-36.
PubMed
11) Wolf CM et al. Subclinical Cardiac Dvsfunction in Childhood Cancer Survivors on 10-Years Follow-Up Correlates With Cumulative Anthracyclinc Dose and Is Best Detected by Cardiopulmonary Exercise Testing, Circulating Serum Biomarker, Speckle Tracking Echocardiography, and Tissue Doppler Imaging. Front Pediatr 2020 ; 8 : 123.
 
12) Wexler LH, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996 ; 14 : 362-72.
PubMed
13) Schloemer NJ, et al. Administration of Dexrazoxane Improves Cardiac Indices in Children and Young Adults With Acute Myeloid Leukemia (AML) While Maintaining Survival Outcomes. J Pediatr Hematol Oncol 2017 ; 39 : e254-8.
 
14) 岡亨, 向井幹. がん治療に伴う心不全と心機能障害のモニタリング. 診断と治療 2018 ; 106 : 919-27.
Medical*Online
P.321 掲載の参考文献
1) 日本小児白血病リンパ腫研究グループ (JPLSG) 長期フォロアップ委員会 (代表石田也寸志) (監訳). 小児がん経験者の長期フォローアップ. 東京 : 日本医学館 ; 2008.
 
2) 石田也寸志. 小児がん経験者の長期フォローアップ. 日小児血液会誌 2008 ; 22 : 144-55.
Medical*Online
3) 石川也寸志, ほか. 小児がん経験者の晩期合併症およびQOLの実態に関する横断的調査研究 第2報. 日小児会誌 2010 ; 114 : 676-86.
 
4) Maeda M. Late effects of childhood cancer : life-threatening issues. J Nippon Med Sch 2008 ; 75 : 320-4.
PubMed
5) 厚生労働科学研究費補助金 難治性疾患等政策研究事業 (難治性疾患政策研究事業) 「小児期発症慢性疾患を持つ移行期患者が疾患の個別性を超えて成人診療へ移行するための診療体制の整備に向けた調査研究」班 (監修). 成人移行支援コアガイド (ver. 1.1). 2020. https://transition-support.jp/about/ (2021年3月21日閲覧)
 
6) Ishizaki Y, et al. Editorial : Advances in Health-Care Transition for Patients With Childhood-Onset Chronic Diseases : International Perspectives. Front Pediatr 2018 : 6 : 80.
PubMed
7) Oeffinger KC, Eshelman DA. Transition Issues. In : Schwartz C, et al (eds). Survivors of Childhood and Adolescent Cancer. Berlin : Springer-Verlag ; 2005. p.333-43.
 
8) Haupt R, et al. Long term survivors of childhood cancer : cure and care. The Erice statement. Eur J Cancer 2007 : 43 : 1778-80.
PubMed
9) 石田也寸志, 細谷亮太. 小児がん治療後のQOL Erice宣言と言葉の重要性-. 日小児会誌 2011 ; 115 : 126-31
 
10) White PH, et al. Supporting the Health Care Transition From Adolescence to Adulthood in the Medical Home. Pediatrics 2018 ; 142 : e20182587.
PubMed
11) Ishida Y, et al. Japanese childhood cancer survivors' readiness for care as adults : a cross-sectional survey using the Transition Scales. Psychooncology 2017 : 26 : 1019-26.
 
12) 石田也寸志, ほか. 小児がん経験者の成人医療移行 への準備状況に関する横断的実態調査. 日小児血がん会誌 2017 ; 53 : 436-47.
 
13) 国立成育医療研究センター小児がんセンター (編). 小児がん経験者のためのトランジション・ステップ 2016 https://www.ncchd.go.jp/hospital/about/section/cancer/leaflet06.pdf (2021年3月21日閲覧)
 
14) Ishida Y, et al. Medical Visits of Childhood Cancer Survivors in Japan : A Cross-sectional Survey. Pediatr Int 2011 ; 53 : 291-9.
PubMed
15) Tonorezos ES, et al. Models of Care for Survivors of Childhood Cancer From Across the Globe : Advancing Survivorship Care in the Next Decade. J Clin Oncol 2018 : 36 : 2223-30.
PubMed
16) 厚生労働省 難病情報報センター. 移行期医療提供体制について. 2019. https://www.nanbyou.or.jp/wp-content/uploads/upload_files/20190516_016.pdf (2021年3月21日閲覧)
 

書評

最近チェックした商品履歴

Loading...